

09/707,320

=>


Uploading 09707320.str

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 16:08:22 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 88001 TO ITERATE

1.1% PROCESSED 1000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

12 ANSWERS

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**

PROJECTED ITERATIONS: EXCEEDS 1000000
PROJECTED ANSWERS: EXCEEDS 19171

L2 12 SEA SSS SAM L1

=>


Uploading 09707320.str

L3 STRUCTURE UPLOADED

=> d

L3 HAS NO ANSWERS

L3 STR



09/707,320

Structure attributes must be viewed using STN Express query preparation.

=> s l3

SAMPLE SEARCH INITIATED 16:11:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1116 TO ITERATE

89.6% PROCESSED 1000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.02


FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 20317 TO 24323
PROJECTED ANSWERS: 1636 TO 2916

L4 50 SEA SSS SAM L3

=> d scan

L4 50 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 3-Piperidinamine, N-[[5-[1-(cyclopropylmethyl)-1H-tetrazol-5-yl]-2-methoxyphenyl]methyl]-2-phenyl-, dihydrochloride, (2S-cis)- (9CI)
MF C24 H30 N6 O . 2 Cl H

Absolute stereochemistry.




●2 HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L4 50 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1,2-Hexanediol, 6-[(2R,3R)-3-[[[5-chloro-2-methoxyphenyl)methyl]amino]-2-phenyl-1-piperidinyl]-, rel- (9CI)
MF C25 H35 Cl N2 O3

Relative stereochemistry.

09/707,320



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s 13 ful

FULL SEARCH INITIATED 16:13:11 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 23265 TO ITERATE

100.0% PROCESSED 23265 ITERATIONS

2249 ANSWERS

SEARCH TIME: 00.00.02

L5 2249 SEA SSS FUL L3

=> file ca,uspatful

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

142.78

142.93

FILE 'CA' ENTERED AT 16:13:30 ON 11 FEB 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:13:30 ON 11 FEB 2002

CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s 15

L6 834 L5

=> s depress? or antidepress? or anxi?

L7 422856 DEPRESS? OR ANTIDEPRESS? OR ANXI?

=> s 16 and 17

L8 134 L6 AND L7

=> s 16(1)17

L9 6 L6(L) L7

=> dup rem 19

PROCESSING COMPLETED FOR L9

L10 6 DUP REM L9 (0 DUPLICATES REMOVED)

=> d 1-6 bib,abs

L10 ANSWER 1 OF 6 CA COPYRIGHT 2002 ACS


AN 136:69737 CA

TI Preparation of 4-[2-(diphenylmethoxy)ethyl]-1-(phenylmethyl)piperidine
analogues with differential CNS dopamine receptor activity and behavior

09/707,320

IN Dutta, Alope K.
PA Wayne State University, USA
SO PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001098266	A2	20011227	WO 2001-US40964	20010614
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 2000-212921	P	20000620		
OS	MARPAT 136:69737				
GI					



AB Title compds. I, II, and III [wherein A and B = independently (un)substituted Ph, 2-furyl, 3-pyridyl, or 2-thienyl; X = NH, NR₄, or O; Y = H, NH₂, OH, :O, or OCOR₅; R = independently H, halo, CN, CO₂Et, OH, NO₂, NH₂, or OR₅; R₄ = (halo)alkyl, NH₂, hydroxyalkyl, (halo)alkenyl, hydroxyalkenyl, or (halo)alkynyl; R₅ = (cyclo)alkyl or alkenyl; with provisos] were prep'd. and exhibited high CNS activity with respect to the dopamine transporter (DAT) and serotonin transporter (SERT). Preferred

compds. exhibited highly differential behavior as between the DAT and SERT and between the DAT and the norepinephrine transporter (NET). For example, 4-[2-(diphenylmethoxy)ethyl]piperidine was reacted with 4-cyanobenzyl bromide, NEt_3 , and K_2CO_3 in DMF to give 4-[2-(diphenylmethoxy)ethyl]-1-[(4-cyanophenyl)methyl]piperidine (84%), which exhibited remarkable selectivity and potency for the DAT ($\text{IC}_{50} = 3.7 \text{ nM}$, $\text{SERT/DAT} = 615$). I, II, and III are useful for treating CNS disorders, including but not limited to cocaine addiction, depression, and Parkinson's disease (no data).

L10 ANSWER 2 OF 6 CA COPYRIGHT 2002 ACS

AN 135:352677 CA

TI Sustained blockade of neurokinin-1 receptors enhances serotonin neurotransmission

AU Haddjeri, N.; Blier, P.

CS Department of Psychiatry, McKnight, Brain Institute, University of Florida, Gainesville, FL, USA

SO Biol. Psychiatry (2001), 50(3), 191-199

CODEN: BIPCBF; ISSN: 0006-3223

PB Elsevier Science Inc.

DT Journal

LA English

AB Antagonists of neurokinin-1 (NK1) receptors, through which substance P acts, have been proposed to belong to a new class of antidepressants with a unique mode of action. It was postulated that they exert this putative therapeutic effect independently of the serotonin (5-HT) neurons. The aim of the present study was to assess, using in vivo electrophysiological paradigms, the effects of sustained administration of the nonpeptidic NK1 antagonist CP-96,345 on the firing activity of rat dorsal raphe 5-HT neurons, the responsiveness of pre- and postsynaptic 5-HT $_1\text{A}$ receptors, and overall 5-HT neurotransmission in the hippocampus. Both short- and long-term treatments with CP-96,345 significantly increased the spontaneous firing activity of dorsal raphe 5-HT neurons, and this increase was associated with an attenuation of somatodendritic 5-HT $_1\text{A}$ autoreceptor responsiveness. In contrast, the inactive enantiomer of CP-96,345 at NK1 receptors, CP-96,344, did not alter these parameters after short-term administration. Because 5-HT $_1\text{A}$ receptor activation inhibits the firing activity of dorsal hippocampus CA3 pyramidal neurons, the degree of disinhibition produced by the selective 5-HT $_1\text{A}$ receptor antagonist WAY 100635 was determined to assess the net change in 5-HT neurotransmission. I.v. injection of WAY 100635 did not disinhibit CA3 pyramidal neuron firing in rats given saline, CP-96,345 for 2 days, or CP-96,344 for 14 days, but produced a significant enhancement of firing in rats treated with CP-96,345 for 2 wk. Therefore, only long-term treatment with CP-96,345 enhanced the tonic activation of postsynaptic 5-HT $_1\text{A}$ receptors. Similar to all other major types of antidepressant treatments, these data indicate that substance P antagonists might alleviate anxiety and major depression, at least in part, by enhancing the degree of activation of some 5-HT receptors in the forebrain.

RE.CNT 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 6 CA COPYRIGHT 2002 ACS

AN 133:99443 CA

TI Pharmacological blockade or genetic deletion of substance P (NK1) receptors attenuates neonatal vocalization in guinea-pigs and mice

AU Rupniak, N. M. J.; Carlson, E. C.; Harrison, T.; Oates, B.; Seward, E.; Owen, S.; de Felipe, C.; Hunt, S.; Wheeldon, A.

CS Merck Sharp and Dohme Neuroscience Research Centre, Essex, CM20 2QR, UK

SO Neuropharmacology (2000), 39(8), 1413-1421

CODEN: NEPHBW; ISSN: 0028-3908

PB Elsevier Science Ltd.

DT Journal

LA English

AB The regulation of stress-induced vocalizations by central NK1 receptors was investigated using pharmacol. antagonists in guinea-pigs, a species with human-like NK1 receptors, and transgenic NK1R-/- mice. In guinea-pigs, i.c.v. infusion of the selective substance P agonist GR73632 (0.1 nmol) elicited a pronounced vocalization response that was blocked enantioselectively by the NK1 receptor antagonists CP-99,994 and L-733,060 (0.1-10 mg/kg). GR73632-induced vocalizations were also markedly attenuated by the antidepressant drugs imipramine and fluoxetine (30 mg/kg), but not by the benzodiazepine anxiolytic diazepam (3 mg/kg) or the 5-HT1A agonist buspirone (10 mg/kg). Similarly, vocalizations in guinea-pig pups sepd. from their mothers were blocked enantioselectively by the highly brain-penetrant NK1 receptor antagonists L-733,060 and GR205171 (ID50 3 mg/kg), but not by the poorly brain-penetrant compds. LY303870 and CGP49823 (30 mg/kg). Sepn.-induced vocalizations were also blocked by the anxiolytic drugs diazepam, chlordiazepoxide and buspirone (ID50 0.5-1 mg/kg), and by the antidepressant drugs phenelzine, imipramine, fluoxetine and venlafaxine (ID50 3-8 mg/kg). In normal mouse pups, GR205171 attenuated neonatal vocalizations when administered at a high dose (30 mg/kg) only, consistent with its lower affinity for the rat than the guinea-pig NK1 receptor. Ultrasound calls in NK1R-/- mouse pups were markedly reduced compared with those in WT pups, confirming the specific involvement of NK1 receptors in the regulation of vocalization. These observations suggest that centrally-acting NK1 receptor antagonists may have clin. utility in the treatment of a range of anxiety and mood disorders.

RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 6 CA COPYRIGHT 2002 ACS

AN 129:67783 CA

TI Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety

IN Baker, Raymond; Curtis, Neil Roy; Elliott, Jason Matthew; Harrison, Timothy; Hollingworth, Gregory John; Jackson, Philip Stephen; Kulagowski, Janusz Jozef; et al.

PA Merck Sharp & Dohme Limited, UK; Baker, Raymond; Curtis, Neil Roy; Elliott, Jason Matthew; Harrison, Timothy; Hollingworth, Gregory John; Jackson, Philip Stephen

SO PCT Int. Appl., 53 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 16

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9824441	A1	19980611	WO 1997-EP6686	19971125
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9855591	A1	19980629	AU 1998-55591	19971125
AU 736042	B2	20010726		

GI



II

AN 129:67781 CA


TI Use of NK-1 receptor antagonists for treating severe anxiety disorders

09/707,320

IN Baker, Raymond; Curtis, Neil Roy; Elliott, Jason Matthew; Harrison, Timothy; Hollingworth, Gregory John; Jackson, Philip Stephen; Kulagowski, Janusz Jozef; Rupniak, Nadia Melanie; et al.
PA Merck Sharp & Dohme Limited, UK; Baker, Raymond; Curtis, Neil Roy; Elliott, Jason Matthew; Harrison, Timothy; Hollingworth, Gregory John; Jackson, Philip Stephen
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 16

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9824439	A1	19980611	WO 1997-EP6683	19971125
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9857527	A1	19980629	AU 1998-57527	19971125
	AU 729708	B2	20010208		
	EP 942734	A1	19990922	EP 1997-953721	19971125
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			
	JP 2001504848	T2	20010410	JP 1998-525170	19971125
	US 6271230	B1	20010807	US 1999-317788	19990524
PRAI	GB 1996-25051	A	19961202		
	GB 1997-1459	A	19970124		
	GB 1997-13715	A	19970627		
	GB 1997-16471	A	19970804		
	GB 1997-21220	A	19971007		
	WO 1997-EP6683	W	19971125		
	US 1997-980928	A3	19971201		

GI



AB The invention provides the use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist, in an oral medicament for the

treatment or prevention of severe anxiety disorders. Also provided are methods of treatment using such an NK-1 receptor antagonist, and pharmaceutical compns. comprising it. Compds. from six prior patent applications, and 15 compds. in particular, are mentioned in claims. Synthetic prepns. of 3 such compds. are given in detail. For instance, (2S,3S)-1-(tert-butoxycarbonyl)-3-hydroxy-2-phenylpiperidine underwent a sequence of alc. oxidn. to the ketone, Grignard reaction with $\text{CH}_2\text{:C}(\text{CH}_2\text{OPh})\text{CH}_2\text{Cl}$, cyclization to give an oxaazaspirodecane system, and ozonolysis of the introduced methylene group, to give (5R,6S)-3-oxo-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)-7-azaspiro[4.5]decane. This ketone was converted to an enol triflate, followed by stannylation, etherification, deprotective hydrogenolysis of an introduced benzyl ether, etherification with 1-iodocyclopropyl Ph sulfide, reductive removal of the PhS moiety, and acidic removal of the BOC group, to give title compd. I, isolated as the HCl salt. Another compd., II, bound to human NK-1 receptor with an IC_{50} of 0.1 nM. II was also active as an NK-1 antagonist in vivo, and in particular in the gerbil foot-tapping test, the ferret cisplatin-induced emesis test, and the guinea pig vocalization assay.

L10 ANSWER 6 OF 6 CA COPYRIGHT 2002 ACS

AN 129:67780 CA

TI Use of NK-1 receptor antagonists for treating major depressive disorders

IN Baker, Raymond; Curtis, Neil Roy; Elliott, Jason Matthew; Harrison, Timothy; Hollingworth, Gregory John; Jackson, Philip Stephen; Kulagowski, Janusz Jozef; Rupniak, Nadia Melanie; et al.

PA Merck Sharp & Dohme Limited, UK; Baker, Raymond; Curtis, Neil Roy; Elliott, Jason Matthew; Harrison, Timothy; Hollingworth, Gregory John; Jackson, Philip Stephen

SO PCT Int. Appl., 51 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 16

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9824438	A1	19980611	WO 1997-EP6682	19971125
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9855589	A1	19980629	AU 1998-55589	19971125
	EP 941092	A1	19990915	EP 1997-952019	19971125
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			
	JP 2001504847	T2	20010410	JP 1998-525169	19971125
	US 6271230	B1	20010807	US 1999-317788	19990524
PRAI	GB 1996-25051	A	19961202		
	GB 1997-1459	A	19970124		
	GB 1997-13715	A	19970627		
	GB 1997-16485	A	19970804		
	GB 1997-21190	A	19971007		
	WO 1997-EP6682	W	19971125		
	US 1997-980928	A3	19971201		

GI



AB The invention provides the use of a CNS-penetrant NK-1 receptor antagonist in an oral, once-a-day medicament for the treatment of major depressive disorders. Also provided are methods of treatment using such an NK-1 receptor antagonist, and pharmaceutical compns. comprising it. Compds. from six prior patent applications, and 15 compds. in particular, are mentioned in claims. Synthetic preps. of 3 such compds. are given in detail. For instance, (2S,3S)-1-(tert-butoxycarbonyl)-3-hydroxy-2-phenylpiperidine underwent a sequence of alc. oxidn. to the ketone, Grignard reaction with $\text{CH}_2\text{:C}(\text{CH}_2\text{OPh})\text{CH}_2\text{Cl}$, cyclization to give an oxazaspirodecane system, and ozonolysis of the introduced methylene group, to give (5R,6S)-3-oxo-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)-7-azaspiro[4.5]decane. This ketone was converted to an enol triflate, followed by stannylation, etherification, deprotective hydrogenolysis of an introduced benzyl ether, etherification with 1-iodocyclopropyl Ph sulfide, reductive removal of the PhS moiety, and acidic removal of the BOC group, to give title compd. I, isolated as the HCl salt. Another compd., II, bound to human NK-1 receptor with IC_{50} of 0.1 nM. II was also active as an NK-1 antagonist in vivo, and in particular in the gerbil foot-tapping test, the ferret cisplatin-induced emesis test, and the guinea pig vocalization assay.

=> s (nk-1 or nk1 or neurokinin-1 or neurokinin1) (2a)antagonist1

1 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> s (nk-1 or nk1 or neurokinin-1 or neurokinin1) (2a)antagonist?

L11 1589 (NK-1 OR NK1 OR NEUROKININ-1 OR NEUROKININ1) (2A) ANTAGONIST?

=> s 16 and l11

L12 303 L6 AND L11

=> s 16(1)l11

L13 115 L6(L) L11

=> dup rem l13

PROCESSING COMPLETED FOR L13

09/707,320

L14 115 DUP REM L13 (0 DUPLICATES REMOVED)

=>

=> d his

(FILE 'HOME' ENTERED AT 16:07:50 ON 11 FEB 2002)

FILE 'REGISTRY' ENTERED AT 16:08:02 ON 11 FEB 2002

L1 STRUCTURE UPLOADED

L2 12 S L1

L3 STRUCTURE UPLOADED

L4 50 S L3

L5 2249 S L3 FUL

FILE 'CA, USPATFULL' ENTERED AT 16:13:30 ON 11 FEB 2002

L6 834 S L5

L7 422856 S DEPRESS? OR ANTIDEPRESS? OR ANXI?

L8 134 S L6 AND L7

L9 6 S L6(L)L7

L10 6 DUP REM L9 (0 DUPLICATES REMOVED)

L11 1589 S (NK-1 OR NK1 OR NEUROKININ-1 OR NEUROKININ1) (2A)ANTAGONIST?

L12 303 S L6 AND L11

L13 115 S L6(L)L11

L14 115 DUP REM L13 (0 DUPLICATES REMOVED)

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	118.74	261.67

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.54	-3.54

FILE 'REGISTRY' ENTERED AT 16:44:44 ON 11 FEB 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 10 FEB 2002 HIGHEST RN 391197-12-9

DICTIONARY FILE UPDATES: 10 FEB 2002 HIGHEST RN 391197-12-9

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES
for more information. See STNote 27, Searching Properties in the CAS
Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

The P indicator for Preparations was not generated for all of the
CAS Registry Numbers that were added to the H/Z/CA/CAplus files between
12/27/01 and 1/23/02. Use of the P indicator in online and SDI searches
during this period, either directly appended to a CAS Registry Number
or by qualifying an L-number with /P, may have yielded incomplete results.
As of 1/23/02, the situation has been resolved. Also, note that searches

09/707,320

conducted using the PREP role indicator were not affected.

Customers running searches and/or SDIs in the H/Z/CA/CAplus files incorporating CAS Registry Numbers with the P indicator between 12/27/01 and 1/23/02, are encouraged to re-run these strategies. Contact the CAS Help Desk at 1-800-848-6533 in North America or 1-614-447-3698, worldwide, or send an e-mail to help@cas.org for further assistance or to receive a credit for any duplicate searches.


```
=> s 3/nr and 2/n and 2/o and 3/x
      3651511 3/NR
      3532097 2/N
      3694617 2/O
      676711 3/X
L15      10571 3/NR AND 2/N AND 2/O AND 3/X
```

```
=> s 15 sub=l15
ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):end
SEARCH ENDED BY USER
```

```
=>
Uploading 09707320.str
```

L16 STRUCTURE UPLOADED

```
=> d
L16 HAS NO ANSWERS
L16 STR
```



Structure attributes must be viewed using STN Express query preparation.

```
=> s 116
SAMPLE SEARCH INITIATED 16:49:39 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 72 TO ITERATE
```

```
100.0% PROCESSED      72 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01
```

50 ANSWERS

09/707,320


FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 931 TO 1949
PROJECTED ANSWERS: 720 TO 1640

L17 50 SEA SSS SAM L16

=> d scan

L17 50 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 3-Piperidinamine, N-[[2-methoxy-5-(2,2,2-trifluoro-1,1-
dimethylethyl)phenyl]methyl]-2-phenyl-, dihydrochloride, (2S-cis)- (9CI)
MF C23 H29 F3 N2 O . 2 Cl H

Absolute stereochemistry.




●2 HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L17 50 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 3-Piperidinamine, N-[[2-methoxy-5-(3,4,5-trimethyl-1H-pyrazol-1-
yl)phenyl]methyl]-2-phenyl-, (2S-cis)- (9CI)
MF C25 H32 N4 O
CI COM

Absolute stereochemistry.




09/707,320

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L17 50 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Phenol, 2-[[[(2S,3S)-2-phenyl-3-piperidiny]amino]methyl]-4-
(trifluoromethoxy)- (9CI)
MF C19 H21 F3 N2 O2
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> d his

(FILE 'HOME' ENTERED AT 16:07:50 ON 11 FEB 2002)

FILE 'REGISTRY' ENTERED AT 16:08:02 ON 11 FEB 2002

L1 STRUCTURE UPLOADED
L2 12 S L1
L3 STRUCTURE UPLOADED
L4 50 S L3
L5 2249 S L3 FUL

FILE 'CA, USPATFULL' ENTERED AT 16:13:30 ON 11 FEB 2002

L6 834 S L5
L7 422856 S DEPRESS? OR ANTIDEPRESS? OR ANXI?
L8 134 S L6 AND L7
L9 6 S L6(L)L7
L10 6 DUP REM L9 (0 DUPLICATES REMOVED)
L11 1589 S (NK-1 OR NK1 OR NEUROKININ-1 OR NEUROKININ1) (2A)ANTAGONIST?
L12 303 S L6 AND L11
L13 115 S L6(L)L11
L14 115 DUP REM L13 (0 DUPLICATES REMOVED)

FILE 'REGISTRY' ENTERED AT 16:44:44 ON 11 FEB 2002

L15 10571 S 3/NR AND 2/N AND 2/O AND 3/X
L16 STRUCTURE UPLOADED

09/707,320

L17 50 S L16

=> s l16 sam sub=l15

SAMPLE SUBSET SEARCH INITIATED 16:51:31 FILE 'REGISTRY'

SAMPLE SUBSET SCREEN SEARCH COMPLETED - 2 TO ITERATE

100.0% PROCESSED 2 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):

ONLINE **COMPLETE**

PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):

2 TO 124

PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):

2 TO 124

L18 2 SEA SUB=L15 SSS SAM L16

=> d scan


L18 2 ANSWERS REGISTRY COPYRIGHT 2002 ACS

IN Phenol, 2-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-4-(trifluoromethoxy)- (9CI)

MF C19 H21 F3 N2 O2

CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L18 2 ANSWERS REGISTRY COPYRIGHT 2002 ACS

IN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, monohydrochloride, (2S,3S)- (9CI)

MF C20 H23 F3 N2 O2 . Cl H

Absolute stereochemistry.

09/707,320



● HCl

ALL ANSWERS HAVE BEEN SCANNED

=> s l16 ful sub=l15

FULL SUBSET SEARCH INITIATED 16:52:06 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED - 28 TO ITERATE

100.0% PROCESSED 28 ITERATIONS

28 ANSWERS

SEARCH TIME: 00.00.01

L19 28 SEA SUB=L15 SSS FUL L16

=> file ca,uspatful

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
159.74	421.41

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-3.54

CA SUBSCRIBER PRICE

FILE 'CA' ENTERED AT 16:52:12 ON 11 FEB 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:52:12 ON 11 FEB 2002

CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l19

L20 61 L19

=> s l20 and (l7 or l11)

L21 43 L20 AND (L7 OR L11)

=> dup rem l21

PROCESSING COMPLETED FOR L21

L22 43 DUP REM L21 (0 DUPLICATES REMOVED)

=> d 1-43 bib,abs,hitstr

L22 ANSWER 1 OF 43 CA COPYRIGHT 2002 ACS

AN 136:102294 CA

TI Preparation of fluoroalkoxybenzylamino derivatives of nitrogen containing

heterocycles as substance P receptor antagonists

IN Chappel, Phillip Branch; O'Neill, Brian Thomas; Saltarelli, Mario David

PA Pfizer Products Inc., USA

SO Eur. Pat. Appl., 44 pp.

CODEN: EPXXDW






DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1172106	A2	20020116	EP 2001-303983	20010501
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002020287	A2	20020123	JP 2001-134144	20010501
PRAI	US 2000-201591	P	20000503		
	US 2000-237780	P	20001004		

GI



AB The present invention relates to methods of treating various central nervous system (CNS) and other disorders or conditions by administering fluoroalkoxybenzylamino derivs. of nitrogen contg. heterocyclic compds., and specifically, by administering compds. of the formula [I; X1 = H, C1-10 alkoxy or alkyl optionally substituted with from one to three fluorine atoms; X2, X3 = halo, H, NO₂, C1-10 alkyl or alkoxy optionally substituted with from one to three fluorine atoms, CF₃, hydroxy, Ph, cyano, amino, C1-6 alkylamino, di(C1-6 alkyl)amino, -CONH-C1-6alkyl, C1-6 alkyl-CONH-C1-6 alkyl, hydroxy-C1-4 alkyl, C1-4 alkoxy-C1-4 alkyl, NHCHO, NHCO-C1-C6 alkyl; Q = N-contg. heterocyclyl, e.g. Q1, Q2, Q3, Q4; R1 = furyl, thienyl, pyridyl, indolyl, biphenyl, (un)substituted phenyl; R13 = C3-4 branched alkyl, C5-6 branched alkenyl, C5-7 cycloalkyl, groups defined in R1; R2 = H, C1-6 alkyl; R3 = each (un)substituted Ph, biphenyl, naphthyl, pyridyl, benzhydryl, thienyl, or furyl; Y = (CH₂)₁ (wherein 1 = an integer from 1 to 3), or cyclohexane-1,2-diyl; Z = O, S, NH, C1-C3 alkyl-NH, (CH₂)_n (wherein n = 0, 1, 2); m = 2, 3; R4 = furyl, thienyl, pyridyl, indolyl, biphenyl, (un)substituted phenyl; R5 = thienyl, biphenyl, (un)substituted phenyl] in a mammal. These compds. I are substance P receptor antagonists (no data). The above CNS and other disorders or conditions include sleep disorders, autism, pervasive development disorder, rheumatoid arthritis, osteoarthritis, fibromyalgia,

human immunodeficiency virus (HIV) infections, dissociative disorders such as body dysmorphic disorders, eating disorder such as anorexia and bulimia, ulcerative colitis, Crohn's disease, irritable bowel syndrome, functional abdominal pain, chronic fatigue syndrome, sudden infant death syndrome (SIDS), overactive bladder, chronic cystitis, chemotherapy induced cystitis, cough, angiotensin converting enzyme (ACE) induced cough, itch, hiccups, premenstrual syndrome, premenstrual dysphoric disorder, schizophrenia, schizoaffective disorder, delusional disorder, substance-induced psychotic disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition, schizophreniform disorder, and amenorrheic disorders such as dysmenorrhea. They also include obesity, epilepsy, movement disorders such as primary movement disorders, spasticities, Scott's syndrome, Tourette's syndrome, palsys, amyolateral sclerosis (ALS), akinetic-rigid disorders, akinesias, dyskinesias, restless leg syndrome and movement disorders assocd. with Parkinson's disease or Huntington's disease, mastalgia syndromes, motion sickness, immune dysfunctions, generalized **anxiety** disorder, panic disorder, phobias including social phobia, agoraphobia, and specific phobias, obsessive-compulsive disorder, posttraumatic stress disorder; **depression** including major **depression**, single episode **depression**, recurrent **depression**, child abuse induced **depression**, postpartum **depression** and dysthemia, cyclothymia, bipolar disorder, neurocardiac disorders such as neurocardiac syncope, neurogenic syncope, hypersensitive Carotid sinus, neurovascular syndrome and arrhythmias including arrhythmias secondary to gastrointestinal disturbances, addiction disorders involving addictions to behaviors, HIV-1 assocd. dementia, AIDS dementia complex, HIV encephalopathy, HIV related neuralgias, AIDS related neuralgias, epilepsy, and attention deficit hyperactivity disorder in a mammal. Thus, reductive alkylation of 2-diphenylmethyl-1-azabicyclo[2.2.2]octan-3-amine by 2-(difluoromethoxy)benzaldehyde using sodium cyanoborohydride in MeOH at room temp. for 30 h gave 2-(Diphenylmethyl)-N-[(2-difluoromethoxy)phenyl]methyl-1-azabicyclo[2.2.2]octan-3-amine.


IT **145742-28-5P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; prepn. of fluoroalkoxybenzylamino derivs. of nitrogen contg. heterocycles as substance P receptor antagonists as therapeutic agents)

RN 145742-28-5 CA

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **145742-21-8P 145742-23-0P 145742-29-6P**
155018-94-3P 157811-47-7P 209666-01-3P
209666-10-4P 209666-12-6P 209666-17-1P

09/707,320

209666-21-7P 209666-22-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of fluoroalkoxybenzylamino derivs. of nitrogen contg. heterocycles as substance P receptor antagonists as therapeutic agents)

RN 145742-21-8 CA

CN 3-Piperidinamine, N-[[2-(1-methylethoxy)-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145742-23-0 CA

CN 3-Piperidinamine, N-[[2-ethoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145742-29-6 CA

CN Phenol, 2-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/707,320

RN 155018-94-3 CA

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, monohydrochloride, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 157811-47-7 CA

CN 3-Piperidinamine, N-[[5-(1,1-dimethylethyl)-2-methoxyphenyl]methyl]-2-[3-(trifluoromethoxy)phenyl]-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209666-01-3 CA

CN Phenol, 2-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-4-(trifluoromethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

09/707,320

RN 209666-10-4 CA

CN 3-Piperidinamine, N-[[2-(1-methylethoxy)-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, monohydrochloride, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 209666-12-6 CA

CN 3-Piperidinamine, N-[[2-ethoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, monohydrochloride, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 209666-17-1 CA

CN 3-Piperidinamine, N-[[5-(1,1-dimethylethyl)-2-methoxyphenyl]methyl]-2-[3-(trifluoromethoxy)phenyl]-, monohydrochloride, (2R,3R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

09/707,320




● HCl

RN 209666-21-7 CA
CN 3-Piperidinamine, N-[[5-(1,1-dimethylethyl)-2-methoxyphenyl]methyl]-2-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 209666-22-8 CA
CN 3-Piperidinamine, N-[[2-(1-methylethoxy)-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl- (9CI) (CA INDEX NAME)



L22 ANSWER 2 OF 43 CA COPYRIGHT 2002 ACS
AN 136:31709 CA
TI Method of treating symptoms of hormonal variation, including hot flashes, using a tachykinin receptor antagonist
IN Guttuso, Thomas J., Jr.
PA University of Rochester, USA
SO PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

09/707,320

PI WO 2001095904 A1 20011220 WO 2001-US40924 20010612
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
US 2002016283 A1 20020207 US 2001-879390 20010612

PRAI US 2000-211116P P 20000612

AB Methods are provided for treating hot flashes and symptoms of hormonal variation in a patient, which methods include providing a tachykinin receptor antagonist and administering the tachykinin receptor antagonist to a patient experiencing a symptom of hormonal variation under conditions effective to treat the symptom of hormonal variation, which symptoms of hormonal variation can include hot flashes.

IT 145742-28-5, CP 122721


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(tachykinin receptor antagonist for treating symptoms of hormonal variation, including hot flashes)

RN 145742-28-5 CA

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 3 OF 43 CA COPYRIGHT 2002 ACS

AN 135:322726 CA

TI A pharmaceutical composition containing a nicotine receptor agonist and an analgesic for treatment of acute, chronic pain and/or neuropathic pain and migraines

IN Coe, Jotham Wadsworth; Harrigan, Edmund Patrick; O'Neill, Brian Thomas; Sands, Steven Bradley; Watsky, Eric Jacob

PA Pfizer Products Inc., USA

SO PCT Int. Appl., 41 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001076576	A2	20011018	WO 2001-IB391	20010316

09/707,320

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2001036943 A1 20011101 US 2000-740307 20001218

PRAI US 2000-195738 P 20000407

AB Oral, parenteral or transdermal compns. are disclosed for the treatment of acute, chronic and/or neuropathic pain. The pharmaceutical compns. are comprised of a therapeutically effective combination of a nicotine receptor partial agonist and an analgesic agent and a pharmaceutically acceptable carrier. The analgesic agent is selected from opioid analgesics, NMDA antagonists, substance P antagonists, COX 1 and COX 2 inhibitors, tricyclic **antidepressants** (TCA), selective serotonin reuptake inhibitors (SSRI), capsaicin receptor agonists, anesthetic agents, benzodiazepines, skeletal muscle relaxants, migraine therapeutic agents, anticonvulsants, antihypertensives, antiarrhythmics, antihistamines, steroids, caffeine, N-type calcium channel antagonists and botulinum toxin. The method of using these compds. and a method of treating acute, chronic and/or neuropathic pain and migraine in a mammal including a human is also disclosed.


IT **145742-28-5**

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. contg. nicotine receptor agonist and analgesic for treatment of acute, chronic pain and/or neuropathic pain and migraines)

RN 145742-28-5 CA

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 4 OF 43 CA COPYRIGHT 2002 ACS

AN 135:117245 CA

TI Substance P receptor antagonist and optional magnesium compound for the treatment of brain, spinal and nerve injury

IN Vink, Robert; Nimmo, Alan John

PA James Cook University, Australia

SO PCT Int. Appl., 22 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.


KIND DATE

APPLICATION NO. DATE

09/707,320

PI WO 2001052844 A1 20010726 WO 2001-AU46 20010118
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRAI AU 2000-5146 A 20000118
AB A treatment for brain, spinal, and nerve injury comprises use of a
substance P receptor antagonist optionally in combination with a magnesium
compd. Also provided is a formulation for use in the treatment comprising
a substance P receptor antagonist and a magnesium compd.
IT **145742-28-5**, CP-122721
RL: BAC (Biological activity or effector, except adverse); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(substance P receptor antagonist and optional magnesium compd. for
treatment of brain, spinal and nerve injury)
RN 145742-28-5 CA
CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-
phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 5 OF 43 CA COPYRIGHT 2002 ACS
AN 135:283167 CA
TI Pharmacophore model, screening method, and identification of cytochrome
P450 enzyme inhibitory potency for **neurokinin-1**
receptor **antagonist**
IN Ekins, Sean; Smith, Bill Joe
PA Pfizer Products Inc., USA
SO Jpn. Kokai Tokkyo Koho, 24 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001275697	A2	20011009	JP 2001-18206	20010126
PRAI	US 2000-178182	P	20000126		
AB	A novel screening method is provided for selecting a neurokinin-1 (NK-1) receptor antagonist compd. which does not possess a significant inhibitory potency towards cytochrome P 450				

enzymes, in particular, CYP2D6. A method is provided for generating a pharmacophore model for a **NK-1** receptor

antagonist compd. which does not possess a significant inhibitory potency towards CYP2D6. A method is provided for discovering a **NK-1** receptor **antagonist** compd. which does not possess a significant inhibitory potency towards the CYP2D6 enzyme. A method is provided for modeling the characteristic groups of the CYP2D6 pharmacophore useful for selecting a **NK-1** receptor

antagonist compd. which does not possess a significant inhibitory potency towards CYP2D6. A pharmaceutical compn. is provided, which contains a **NK-1** receptor **antagonist** compd. that does not possess a significant inhibitory potency towards the CYP2D6 enzyme. A **NK-1** receptor **antagonist** identified by this method can be used for manufg. medicaments and for treating a condition, a disorder or a disease in a mammal.


IT 145742-21-8 145742-23-0 145742-28-5

RL: BAC (Biological activity or effector, except adverse); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmacophore model, screening method, and identification of cytochrome P 450 enzyme inhibitory potency for **neurokinin-1** receptor **antagonist**)

RN 145742-21-8 CA

CN 3-Piperidinamine, N-[[2-(1-methylethoxy)-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145742-23-0 CA

CN 3-Piperidinamine, N-[[2-ethoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 145742-28-5 CA

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/707,320



L22 ANSWER 6 OF 43 CA COPYRIGHT 2002 ACS
AN 135:71306 CA
TI **NK-1 receptor antagonists** for the treatment
of symptoms of irritable bowel syndrome
IN Williams, Stephen A.
PA USA
SO U.S. Pat. Appl. Publ., 9 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2001006972	A1	20010705	US 1998-63664	19980421
OS	MARPAT 135:71306				
AB	A method is provided for treating or preventing symptoms (e.g. abdominal pain) of irritable bowel syndrome in a mammal, including a human, using a compd. that is an NK-1 receptor antagonist , in particular a substance P receptor antagonist.				
IT	145742-28-5 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (NK-1 receptor antagonists for treatment of symptoms of irritable bowel syndrome such as abdominal pain)				
RN	145742-28-5 CA				
CN	3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



L22 ANSWER 7 OF 43 USPATFULL
AN 2001:194428 USPATFULL
TI Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
IN Coe, Jotham W., Niantic, CT, United States

09/707,320

Sands, Steven B., Stonington, CT, United States
Harrigan, Edmund P., Old Lyme, CT, United States
O'Neill, Brian T., Old Saybrook, CT, United States
Watsky, Eric J., Stonington, CT, United States

PI US 2001036943 A1 20011101
AI US 2000-740307 A1 20001218 (9)
PRAI US 2000-195738 20000407 (60)
DT Utility
FS APPLICATION
LREP Paul H. Ginsburg, Pfizer Inc, 20th Floor, 235 East 42nd Street, New York, NY, 10017-5755
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1917

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical compositions are disclosed for the treatment of acute, chronic and/or neuropathic pain. The pharmaceutical compositions are comprised of a therapeutically effective combination of a nicotine receptor partial agonist and an analgesic agent and a pharmaceutically acceptable carrier. The analgesic agent is selected from opioid analgesics, NMDA antagonists, substance P antagonists, COX 1 and COX 2 inhibitors, tricyclic **antidepressants** (TCA), selective serotonin reuptake inhibitors (SSRI), capsaicin receptor agonists, anesthetic agents, benzodiazepines, skeletal muscle relaxants, migraine therapeutic agents, anti-convulsants, anti-hypertensives, anti-arrhythmics, antihistamines, steroids, caffeine, and botulinum toxin. The method of using these compounds and a method of treating acute, chronic and/or neuropathic pain and migraine in a mammal including a human is also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT **145742-28-5**

(compos. contg. nicotine receptor agonist and analgesic for treatment of acute, chronic pain and/or neuropathic pain and migraines)

RN 145742-28-5 USPATFULL

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 8 OF 43 USPATFULL

AN 2001:105353 USPATFULL

TI **NK-1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SYMPTOMS OF IRRITABLE BOWEL SYNDROME**

IN WILLIAMS, STEPHEN A., NORTH STONINGTON, CT, United States

PI US 2001006972 A1 20010705

AI US 1998-63664 A1 19980421 (9)

09/707,320

DT Utility
FS APPLICATION
LREP PFIZER INC, 235 E 42ND STREET, NEW YORK, NY, 10017
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 700

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method of treating or preventing symptoms of irritable bowel syndrome in a mammal, including a human, using a compound that is an **NK-1** receptor **antagonist**, in particular a substance P receptor antagonist.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT **145742-28-5**

(NK-1 receptor antagonists for treatment of symptoms of irritable bowel syndrome such as abdominal pain)

RN 145742-28-5 USPATFULL

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 9 OF 43 USPATFULL

AN 2001:226651 USPATFULL

TI Substituted benzylaminopiperidine compounds

IN Satake, Kunio, Handa, Japan

Shishido, Yuji, Aichi-ken, Japan

Wakabayashi, Hiroaki, Kariya, Japan

PA Pfizer Inc., New York, NY, United States (U.S. corporation)

PI US 6329396 B1 20011211

AI US 2000-562144 20000501 (9)

RLI Division of Ser. No. US 11271, now abandoned

DT Utility

FS GRANTED

EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Rao, Deepak R.

LREP Richardson, Peter C., Ginsburg, Paul H., Waldron, Roy F.

CLMN Number of Claims: 5

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1785

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a substituted benzylaminopiperidine compounds that are useful in the treatment of gastrointestinal disorders; central nervous system (CNS) disorders; inflammatory disease; emesis; urinary incontinence; pain; migraine; sunburn; diseases, disorders and adverse conditions caused by *Helicobacter pylori*; or angiogenesis, especially CNS disorders in a mammalian subject, especially in humans.

09/707,320

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT **188725-71-5P**

(prepn. of substituted benzylaminopiperidines as substance P antagonists)

RN 188725-71-5 USPATFULL

CN 3-Piperidinamine, N-[[2,4-dimethoxy-5-(2,2,2-trifluoroethyl)phenyl]methyl]-2-phenyl-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 10 OF 43 USPATFULL

AN 2001:29588 USPATFULL

TI **NK-1 receptor antagonists** for the treatment of cancer

IN Howard, Harry Ralph, Bristol, CT, United States

PA Pfizer Inc., New York, NY, United States (U.S. corporation)

PI US 6194436 B1 20010227

AI US 1999-334369 19990616 (9)

RLI Continuation of Ser. No. US 1997-786128, filed on 17 Jan 1997, now patented, Pat. No. US 5990125

PRAI US 1996-10232 19960119 (60)

DT Utility

FS Granted

EXNAM Primary Examiner: Spivack, Phyllis G.

LREP Richardson, Peter C., Ginsburg, Paul H., Appleman, Jolene W.

CLMN Number of Claims: 1

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1768

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the use of certain **NK-1 receptor antagonists**, as, for example, substance P receptor antagonists, to treat cancer patients, particularly cancer patients afflicted with a small cell lung carcinoma, neuroendocrine tumor or extrapulmonary small cell carcinoma.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **145742-21-8 145742-23-0 145742-28-5 157811-47-7**


(Nk-1 receptor antagonists for the treatment of cancer)

RN 145742-21-8 USPATFULL

CN 3-Piperidinamine, N-[[2-(1-methylethoxy)-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/707,320



RN 145742-23-0 USPATFULL

CN 3-Piperidinamine, N-[[2-ethoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145742-28-5 USPATFULL

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 157811-47-7 USPATFULL

CN 3-Piperidinamine, N-[[5-(1,1-dimethylethyl)-2-methoxyphenyl]methyl]-2-[3-(trifluoromethoxy)phenyl]-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 11 OF 43 CA COPYRIGHT 2002 ACS

AN 136:482 CA

TI P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related **neurokinin-1 receptor antagonists**

AU Smith, Bill J.; Doran, Angela C.; McLean, Stafford; Tingley, F. David, III; O'Neill, Brian T.; Kajiji, Shama M.

CS Neurosciences Discovery, Departments of Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Groton Laboratories, Pfizer, Inc., Groton, CT, USA

SO Journal of Pharmacology and Experimental Therapeutics (2001), 298(3), 1252-1259

CODEN: JPETAB; ISSN: 0022-3565

PB American Society for Pharmacology and Experimental Therapeutics

DT Journal

LA English

AB CP-122721 and CP-141938 are potent and selective **neurokinin-**

1 (NK1) receptor antagonists with very

different brain disposition and potency in models of centrally mediated activity. These investigations sought to det. whether differences in potency were related to differences in P-glycoprotein (P-gp) transport at the blood-brain barrier. Both compds. stimulated ATPase activity of human recombinant MDR1 with similar kinetic parameters. Cell-assocd. drug concns. of CP-141938 were 9.4-fold lower in KBV1 cells expressing P-gp compared with KB3.1 control cells. In Madin-Darby canine kidney (MDCK) cells expressing human MDR1, asym. transport of CP-141938 was 5-fold higher than in wild-type MDCK cells, whereas no asymmetry was obsd. with CP-122721. In agreement with these differences in cellular transport, the differences in brain/plasma ratio between mdrla/b(-/-) and FVB mice 1 h following a 3 mg/kg s.c. dose were 3- and 50-fold for CP-122721 and CP-141938, resp. The effect of inhibiting P-gp efflux on the effects of these agents was evaluated using GR73632-induced foot tapping in gerbils as a model to measure centrally mediated NK1 antagonism. When gerbils were pretreated with the P-gp inhibitor MS-073 (50 mg/kg s.c.), there was no effect on the activity of CP-122721 (0.05 mg/kg), whereas the percent reversal for CP-141938 (10 mg/kg) increased from 60 to 100%. In gerbils, the brain/plasma ratio for CP-122721 was unaffected by MS-073 pretreatment, whereas the brain/plasma ratio for CP-141938 brain concns. increased 13-fold. This suggested that P-gp efflux influences the brain disposition and pharmacol. activity of CP-141938, but not CP-122721. Complete response curves for CP-141938 were then detd. with respect to dose, and drug concn. in the plasma and brain in the presence and absence of MS-073 pretreatment. The dose and plasma concn.-response curves of CP-141938 were shifted to the left in the presence of MS-073, yet brain concns. assocd. with the response were unchanged. This suggested that once in the brain the interaction of CP-141938 with the NK1 receptor was

09/707,320

not affected by P-gp transport. In conclusion, these studies show that brain disposition and centrally mediated in vivo activity of **NK1 antagonists** can be profoundly affected by P-gp transport and that such transport should be considered during the design of new agents.

IT 145742-28-5, CP-122721


RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(P-glycoprotein efflux at blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related **neurokinin-1** receptor **antagonists**)

RN 145742-28-5 CA

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 12 OF 43 CA COPYRIGHT 2002 ACS

AN 134:13350 CA

TI Nitric oxide synthase (NOS) inhibitor combinations with other agents for treatment of disorders treatable by altering circadian rhythm

IN Saltarelli, Mario David; Lowe, John Adams, III

PA Pfizer Products Inc., USA

SO PCT Int. Appl., 113 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000071107	A2	20001130	WO 2000-IB295	20000316
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRAI US 1999-135520 P 19990521


AB New pharmaceutical uses are provided for compds. that exhibit activity as NOS inhibitors. Specifically, the invention provides the use of NOS inhibitors, particularly selective neuronal NOS (nNOS) inhibitors, alone or in combination with another active agent, in particular, either a selective serotonin reuptake inhibitor (SSRI) or an **NK-1**

receptor **antagonist**, for the treatment of disorders or conditions the treatment which can be effected or facilitated by altering circadian rhythms. Examples of such disorders and conditions are blindness, obesity, seasonal affective disorder, bipolar disorder, jet lag, circadian sleep rhythms disorder, sleep deprivation, parasomnias, REM sleep disorders, hypersomnia, sleep-wake cycle disorders, narcolepsy and sleep disorders assocd. with shift work or irregular work schedules; nocturnal enuresis, and restless-legs syndrome.

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


RN 145742-21-8 CA

Absolute stereochemistry.



RN 145742-23-0 CA


Absolute stereochemistry.



RN 145742-28-5 CA

Absolute stereochemistry.


09/707,320



RN 145742-29-6 CA

CN Phenol, 2-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 147249-26-1 CA

CN 3-Piperidinamine, N-[[[5-(1,1-dimethylethyl)-2-methoxyphenyl]methyl]-2-[3-(trifluoromethoxy)phenyl]-, (2R,3R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 157811-47-7 CA

CN 3-Piperidinamine, N-[[[5-(1,1-dimethylethyl)-2-methoxyphenyl]methyl]-2-[3-(trifluoromethoxy)phenyl]-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 13 OF 43 CA COPYRIGHT 2002 ACS
 AN 133:301178 CA
 TI Use of CYP2D6 inhibitors in combination therapies
 IN Obach, Ronald Scott
 PA Pfizer Products Inc., USA
 SO PCT Int. Appl., 18 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000059486	A2	20001012	WO 2000-IB304	20000320
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	BR 2000009564	A	20020108	BR 2000-9564	20000320
	NO 2001004858	A	20011205	NO 2001-4858	20011005
PRAI	US 1999-128136P	P	19990407		
	WO 2000-IB304	W	20000320		

AB This invention relates to the use of a CYP2D6 inhibitor in combination with a drug having CYP2D6-catalyzed metab., wherein the drug and the CYP2D6 inhibitor are not the same compd.; and pharmaceutical compns. for said use.

IT **145742-28-5**


RL: BAC (Biological activity or effector, except adverse); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(use of CYP2D6 inhibitors in combination therapies)

RN 145742-28-5 CA


CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 14 OF 43 CA COPYRIGHT 2002 ACS
 AN 132:288426 CA
 TI Probable involvement of the 5-hydroxytryptamine₄ receptor in methotrexate-induced delayed emesis in dogs
 AU Yamakuni, Hisashi; Sawai, Hiroe; Maeda, Yasue; Imazumi, Katsunori; Sakuma, Hiroyuki; Matsuo, Masahiko; Mutoh, Seitaro; Seki, Jiro
 CS Department of Metabolic Diseases, Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan
 SO J. Pharmacol. Exp. Ther. (2000), 292(3), 1002-1007
 CODEN: JPETAB; ISSN: 0022-3565
 PB American Society for Pharmacology and Experimental Therapeutics
 DT Journal
 LA English
 AB Delayed emesis in cancer patients undergoing chemotherapy remains a significant problem. The pathogenesis of delayed emesis is still obscure. It was recently demonstrated that methotrexate (MTX), an anticancer drug, evoked delayed emesis in dogs in a manner similar to its actions in humans. We evaluated the antiemetic activity of FK1052, a potent antagonist for both the 5-hydroxytryptamine (HT)₃ and 5-HT₄ receptors, on delayed emesis induced by MTX in beagle dogs. Animal behavior was recorded for 3 days using a video camera. Delayed emesis lasting up to 72 h was obsd. in dogs treated with MTX (2.5 mg/kg i.v.), but acute emesis did not occur. The following antiemetics, at the dose that prevents cisplatin-induced acute emesis in dogs, were administered i.v. as multiple injections every 12 h during days 2 to 3. FK1052 (1 and 3.2 mg/kg) significantly reduced the emetic episodes caused by MTX, whereas ondansetron (1 mg/kg), a selective 5-HT₃ receptor antagonist, was not effective. The emetic episodes induced by MTX were also inhibited by another 5-HT_{3/4} receptor antagonist, tropisetron (1 mg/kg). CP-122,721 (0.1 mg/kg), a potent selective tachykinin **NK1** receptor antagonist, significantly reduced the emetic responses to MTX. Copper sulfate-induced emesis in dogs was also prevented by FK1052, tropisetron, and CP-122,721 but not by ondansetron. FK1052, tropisetron, and ondansetron had negligible affinity for the NK1 receptor at 1 μ M. These results suggest that the 5-HT₄ receptor may be in part involved in the prodn. of delayed emesis induced by MTX in dogs and that FK1052 may be a useful drug against both acute and delayed emesis induced by cancer chemotherapy.
 IT **145742-28-5**, CP-122721
 RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (probable involvement of the 5-hydroxytryptamine₄ receptor in methotrexate-induced delayed emesis in dogs)
 RN 145742-28-5 CA
 CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 15 OF 43 CA COPYRIGHT 2002 ACS

AN 134:336119 CA

TI Substance P (**neurokinin-1**) **antagonist**

prevents postoperative vomiting after abdominal hysterectomy procedures
AU Gesztes, Zsuzsanna; Scuderi, Phillip E.; White, Paul F.; Wright, William;
Wender, Ronald H.; D'Angelo, Robert; Black, L. Suzanna; Dalby, Patricia
L.; MacLean, David

CS Departments of Anesthesiology and Pain Management, University of Texas
Southwestern Medical Center, Dallas, TX, 75235-9068, USA

SO Anesthesiology (2000), 93(4), 931-937

CODEN: ANESAV; ISSN: 0003-3022

PB Lippincott Williams & Wilkins

DT Journal

LA English

AB The safety and antiemetic efficacy of CP-122,721, a novel **neurokinin-1 antagonist**, was evaluated when administered alone or in combination with ondansetron. Using a randomized, double-blind, placebo-controlled study design, CP-122,721 was initially compared with placebo and subsequently to ondansetron alone and in combination for prophylaxis against postoperative nausea and vomiting in 243 women undergoing abdominal hysterectomy. In the dose-ranging studies (n = 86), patients received either CP-122,721 100 mg (vs. placebo) or 200 mg (vs. placebo) orally 60-90 min before induction of anesthesia. In the interaction study (n = 157), patients received CP-122,721 200 mg or placebo 60-90 min before induction of anesthesia, and ondansetron 4 mg or saline 2 mL i.v. 15-30 min before the end of surgery. Patients assessed their level of nausea and pain on arrival in the postanesthesia care unit and at 0.5-, 1-, 1.5-, 2-, 4-, 8-, 12-, and 24-h intervals postoperatively. Emetic episodes, need for rescue antiemetic-antinausea medication, postoperative complications, and patient satisfaction were recorded. In the initial dose-ranging study, only 10% of the patients experienced emesis within the first 8 h after surgery with CP-122,721 200 mg compared with 50% in the placebo group. CP-122,721 200 mg also decreased the need for rescue medication (25% vs. 48%). CP-122,721 100 mg was less effective than 200 mg in decreasing the incidence of repeated episodes of emesis. In the interaction study, 6% of the patients receiving CP-122,721 200 mg orally experienced emesis less than 2 h after surgery compared with 17% with ondansetron alone. With combined therapy, only 2% experienced emesis. In addn., the median times for 75% of patients to remain free from postoperative nausea and vomiting were 82, 75, and 362 min in the ondansetron, CP-122,721, and combination groups, resp. Oral CP-122,721 200 mg decreased emetic episodes compared with ondansetron (4 mg i.v.) during the first 24 h after gynecol. surgery; however, there was no difference in patient satisfaction.

IT 145742-28-5, CP-122721


09/707,320

RL: BAC (Biological activity or effector, except adverse); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(**neurokinin-1 antagonist** prevents
postoperative vomiting after abdominal hysterectomy procedures)

RN 145742-28-5 CA

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 16 OF 43 CA COPYRIGHT 2002 ACS

AN 130:191898 CA

TI Substance P inhibitors in combination with NMDA blockers for treating pain

IN Caruso, Frank S.

PA Algos Pharmaceutical Corporation, USA

SO PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9907413	A1	19990218	WO 1998-US10707	19980526
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9876960	A1	19990301	AU 1998-76960	19980526
PRAI	US 1997-55233		19970811		
	WO 1998-US10707		19980526		

AB The analgesic effectiveness of a substance P receptor antagonist is significantly potentiated by administering a substance P receptor antagonist with a nontoxic NMDA receptor antagonist and/or a nontoxic substance that blocks at least one major intracellular consequence of NMDA receptor activation.

IT 145742-21-8 145742-23-0 157811-47-7

RL: BAC (Biological activity or effector, except adverse); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)


(substance P inhibitor-NMDA blocker combination for treating pain)

RN 145742-21-8 CA

CN 3-Piperidinamine, N-[[2-(1-methylethoxy)-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

09/707,320


Absolute stereochemistry.



RN 145742-23-0 CA

CN 3-Piperidinamine, N-[[2-ethoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 157811-47-7 CA

CN 3-Piperidinamine, N-[[5-(1,1-dimethylethyl)-2-methoxyphenyl]methyl]-2-[3-(trifluoromethoxy)phenyl]-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 17 OF 43 USPATFULL

AN 1999:151228 USPATFULL

TI **NK-1 receptor antagonists** for the
treatment of cancer

IN Howard, Harry Ralph, Bristol, CT, United States

PA Pfizer Inc., New York, NY, United States (U.S. corporation)

PI US 5990125 19991123

AI	US 1997-786128	19970117 (8)
PRAI	US 1996-10232	19960119 (60)
DT	Utility	
FS	Granted	
EXNAM	Primary Examiner: Goldberg, Jerome D.	
LREP	Richardson, Peter C., Ginsburg, Paul H., Dryer, Mark	
CLMN	Number of Claims: 1	
ECL	Exemplary Claim: 1	
DRWN	No Drawings	
LN.CNT	1732	

AB The present invention relates to the use of certain **NK-1** receptor **antagonists** (e.g., substance P receptor antagonists) to treat cancer patients, particularly cancer patients afflicted with a small cell lung carcinoma, APUDoma, astrocytoma, neuroendocrine tumor or extrapulmonary small cell carcinoma.

IT 145742-21-8 145742-23-0 145742-28-5
157811-47-7

RN 145742-21-8 USPATFULL

CN 3-Piperidinamine, N-[[2-(1-methylethoxy)-5-(trifluoromethoxy)phenyl]methyl
]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

COc1cc(OC(F)(F)F)ccc1CNc2c[nH]c3ccccc23


CN 3-Piperidinamine, N-[[2-ethoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-
, (2S,3S)- (9CI) (CA INDEX NAME)

CCOC1=CC=C(OC(F)(F)F)C=C1CN2C(=N)SCC2c3ccccc3

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/707,320



RN 157811-47-7 USPTAFULL

CN 3-Piperidinamine, N-[[5-(1,1-dimethylethyl)-2-methoxyphenyl]methyl]-2-[3-(trifluoromethoxy)phenyl]-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 18 OF 43 CA COPYRIGHT 2002 ACS

AN 130:320650 CA

TI Inhibition of emesis by tachykinin **NK1** receptor **antagonists** in *Suncus murinus* (house musk shrew)

AU Rudd, John A.; Ngan, Man P.; Wai, Man K.

CS Shatin, Faculty of Medicine, Department of Pharmacology, The Chinese University of Hong Kong, Hong Kong, Peop. Rep. China

SO Eur. J. Pharmacol. (1999), 366(2/3), 243-252

CODEN: EJPHAZ; ISSN: 0014-2999

PB Elsevier Science B.V.

DT Journal

LA English

AB The anti-emetic potential of CP-122721 ((+)-(2S,3S)-3-(2-methoxy-5-trifluoromethoxybenzyl)amino-2-phenylpiperidine), CP-99994 ((+)-(2S,3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine), CP-100263 ((-)-(2R,3R)-3-(2-methoxybenzylamino)-2-phenylpiperidine), RP 67580 ((3R,7aR)-7, 7-diphenyl-2-[1-imino-2-(2-methoxyphenyl)ethyl]po-hydroisoindol-4-one), FK 888 (N2-[(4R)-4-hydroxy-1-(1-methyl-1H-indole-3-yl) carbonyl-1-propyl] -N- methyl-N-phenylmethyl-1-3-(2-naphthyl)-alaninamide) and GR 82334 ([d-Pro9{spiro-g-lactam}Leu10]-physalemin-(1-11)) was investigated to inhibit nicotine (5 mg/kg, s.c.)-, copper sulfate pentahydrate (120 mg/kg, intragastric)- and motion (4 cm horizontal displacement at 1 Hz for 5 min)-induced emesis in *Suncus murinus*. A 30 min i.p. pre-treatment with CP-122721, CP-99994, RP 67580 and FK 888 significantly ($P < 0.05$) antagonized nicotine-induced emesis with ID50 values of 2.1, 2.3, 13.5 and 19.2 mg/kg, resp. CP-100263, the less active enantiomer of CP-99994, was inactive at doses up to 10 mg/kg. Infusion of GR 82334, CP-122721, CP-99994 and FK 888 into the dorsal vagal complex of

09/707,320

the hindbrain also antagonized nicotine-induced emesis yielding ID50 values of 1.1, 3.0, 3.3 and 58.0 .mu.g/dorsal vagal complex, resp. RP 67580 and CP-100263 were inactive. RP 67580 and FK 888 failed to antagonize copper sulfate-induced emesis but CP-122721 and CP-99994 were active yielding ID50 values of 2.2 and 3.0 mg/kg, i.p., resp. CP-99994 also completely prevented motion-induced emesis at 10 mg/kg, i.p. (P<0.05) and RP 67580 produced a significant redn. of motion-induced emesis at 10 mg/kg, i.p. (P<0.05). These studies provide evidence of a central site of action of tachykinin **NK1** receptor **antagonists** to inhibit nicotine-induced emesis in *S. murinus* and confirm the broad profile of inhibitory action. The rank order of potency of the antagonists following the intra-dorsal vagal complex administration suggests that the *S. murinus* tachykinin NK1 receptor has a unique pharmacol. profile.

IT **145742-28-5**, CP-122721


RL: BAC (Biological activity or effector, except adverse); BIOL
(Biological study)

(inhibition of emesis by tachykinin **NK1** receptor
antagonists in *Suncus murinus* (house musk shrew))

RN 145742-28-5 CA

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 19 OF 43 CA COPYRIGHT 2002 ACS

AN 129:604 CA

TI Substance P antagonists capable of crossing blood-brain barrier for treatment of CNS disease-linked dyskinesia

IN Imperato, Assunta; Moussaoui, Saliha; Obinu, Carmen; Gobbo, Olivier

PA Rhone-Poulenc Rorer S.A., Fr.; Imperato, Assunta; Moussaoui, Saliha; Obinu, Carmen; Gobbo, Olivier

SO PCT Int. Appl., 44 pp.

CODEN: PIXXD2

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9818465	A1	19980507	WO 1997-FR1914	19971024
	W:	AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,			

09/707,320

GN, ML, MR, NE, SN, TD, TG

FR 2755013	A1	19980430	FR 1996-13175	19961029
FR 2755013	B1	19981127		
AU 9749514	A1	19980522	AU 1997-49514	19971024
PRAI FR 1996-13175		19961029		
WO 1997-FR1914		19971024		


AB The invention concerns the use of substance P antagonists, capable of passing through the blood-brain barrier, for prepg. a medicine for the treatment of dyskinesia linked with diseases of the central nervous system, e.g. tardive dyskinesia.

IT **145877-52-7**
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substance P antagonists capable of crossing blood-brain barrier for treatment of CNS disease-linked dyskinesia)

RN 145877-52-7 CA

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, dihydrochloride, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

L22 ANSWER 20 OF 43 CA COPYRIGHT 2002 ACS

AN 129:270622 CA

TI Use of **NK-1** receptor **antagonists** for manufacture of a medicament for treating emesis

IN Nagahisa, Atsushi; Tsuchiya, Megumi; Silberman, Sandra Leta

PA Pfizer Inc., USA

SO Eur. Pat. Appl., 7 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 867182	A2	19980930	EP 1998-302214	19980324
	EP 867182	A3	20000223		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 10287567	A2	19981027	JP 1998-75886	19980324
	JP 2955550	B2	19991004		
	CA 2233377	AA	19980928	CA 1998-2233377	19980326
	AU 9859660	A1	19981001	AU 1998-59660	19980326
	ZA 9802603	A	19990927	ZA 1998-2603	19980327
PRAI	US 1997-42038	P	19970328		

09/707,320


AB Pharmaceutical compns. contg. (2S,3S)-3-(2-methoxy-5-trifluoromethoxybenzyl)amino-2-phenylpiperidine, (2S,3S)-N-(5-tert-butyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]octan-3-amine, or (2S,3S)-N-(5-isopropyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]octan-3-amine or their pharmaceutically acceptable salts are useful for preventing or treating delayed emesis in mammals such as occurs during chemotherapy with cisplatin (no data).

IT **145742-28-5**
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of **NK-1** receptor **antagonists** for treating emesis)

RN 145742-28-5 CA

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 21 OF 43 USPATFULL

AN 1998:75596 USPATFULL

TI Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles

IN Lowe, III, John Adams, Stonington, CT, United States
Rosen, Terry Jay, Foster City, CA, United States

PA Pfizer Inc., New York, NY, United States (U.S. corporation)

PI US 5773450 19980630
WO 9206079 19920416

AI US 1993-167881 19931214 (8)
WO 1992-US3571 19920505
19931214 PCT 371 date
19931214 PCT 102(e) date

RLI Continuation-in-part of Ser. No. US 1991-717943, filed on 20 Jun 1991, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Wu, Shean C.

LREP Richardson, Peter C., Ginsburg, Paul H., DeBenedictis, Karen

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1730

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel fluoroalkoxybenzylamino derivatives of nitrogen containing heterocyclic compounds, and specifically, to compounds of the formula ##STR1## wherein Q, X.sup.1, x.sup.2 and X.sup.3 are as defined below. These novel compounds are useful in the treatment of inflammatory and central nervous system disorders, as well as other disorders.

09/707,320

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 145742-28-5P 145742-29-6P 155018-94-3P

209666-01-3P 209666-10-4P 209666-12-6P


209666-17-1P 209666-21-7P 209666-22-8P

(prepn. of [(Fluoroalkoxy)benzylamino]piperidine derivs. as substance P receptor antagonists as central nervous system agents and antiinflammatory agents)

RN 145742-28-5 USPATFULL

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145742-29-6 USPATFULL

CN Phenol, 2-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 155018-94-3 USPATFULL

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, monohydrochloride, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09/707,320




● HCl

RN 209666-01-3 USPATFULL

CN Phenol, 2-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-4-(trifluoromethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 209666-10-4 USPATFULL

CN 3-Piperidinamine, N-[[2-(1-methylethoxy)-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, monohydrochloride, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 209666-12-6 USPATFULL

CN 3-Piperidinamine, N-[[2-ethoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-

09/707,320

, monohydrochloride, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 209666-17-1 USPATFULL

CN 3-Piperidinamine, N-[[5-(1,1-dimethylethyl)-2-methoxyphenyl]methyl]-2-[3-(trifluoromethoxy)phenyl]-, monohydrochloride, (2R,3R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 209666-21-7 USPATFULL

CN 3-Piperidinamine, N-[[5-(1,1-dimethylethyl)-2-methoxyphenyl]methyl]-2-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



COc1ccc(cc1)CNCC2CCCCC2Nc3ccc(OC(F)(F)F)cc3

CN 3-Piperidinamine, N-[[2-(1-methylethoxy)-5-(trifluoromethoxy)phenyl]methyl
]-2-phenyl- (9CI) (CA INDEX NAME)



AB The present invention relates to novel fluoroalkoxybenzylamino derivatives of nitrogen containing heterocyclic compounds, and specifically, to compounds of the formula ##STR1## wherein Q, X.sup.1, X.sup.2 and X.sup.3 are as defined below. These novel compounds are useful in the treatment of inflammatory and central nervous system disorders, as well as other disorders.


IT 145742-21-8P 145742-23-0P 145742-28-5P
145742-29-6P 145877-45-8P 145877-47-0P
145877-52-7P 145877-53-8P 147232-03-9P
147249-26-1P
(prepn. of, as substance P antagonist)

09/707,320

RN 145742-21-8 USPATFULL

CN 3-Piperidinamine, N-[[2-(1-methylethoxy)-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145742-23-0 USPATFULL

CN 3-Piperidinamine, N-[[2-ethoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145742-28-5 USPATFULL

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 145742-29-6 USPATFULL

CN Phenol, 2-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/707,320



RN 145877-45-8 USPATFULL

CN 3-Piperidinamine, N-[[2-(1-methylethoxy)-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, dihydrochloride, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 145877-47-0 USPATFULL

CN 3-Piperidinamine, N-[[2-ethoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, dihydrochloride, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 145877-52-7 USPATFULL

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, dihydrochloride, (2S,3S)- (9CI) (CA INDEX NAME)

09/707,320

Absolute stereochemistry.




●2 HCl

RN 145877-53-8 USPATFULL

CN Phenol, 2-[[2-(2-phenyl-3-piperidinyl)amino]methyl]-4-(trifluoromethoxy)-, dihydrochloride, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 147232-03-9 USPATFULL

CN 3-Piperidinamine, N-[[5-(1,1-dimethylethyl)-2-methoxyphenyl]methyl]-2-[3-(trifluoromethoxy)phenyl]-, hydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.

09/707,320




● x HCl

RN 147249-26-1 USPATFULL

CN 3-Piperidinamine, N-[[5-(1,1-dimethylethyl)-2-methoxyphenyl)methyl]-2-[3-(trifluoromethoxy)phenyl]-, (2R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L22 ANSWER 23 OF 43 CA COPYRIGHT 2002 ACS

AN 130:20189 CA

TI Structural Optimization Affording 2-(R)-(1-(R)-3,5-Bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a Potent, Orally Active, Long-Acting Morpholine Acetal Human **NK-1** Receptor

Antagonist

AU Hale, Jeffrey J.; Mills, Sander G.; MacCoss, Malcolm; Finke, Paul E.; Cascieri, Margaret A.; Sadowski, Sharon; Ber, Elzbieta; Chicchi, Gary G.; Kurtz, Marc; Metzger, Joseph; Eiermann, George; Tsou, Nancy N.; Tattersall, F. David; Rupniak, Nadia M. J.; Williams, Angela R.; Rycroft, Wayne; Hargreaves, Richard; MacIntyre, D. Euan

CS Merck Research Laboratories, Rahway, NJ, 07065, USA

SO J. Med. Chem. (1998), 41(23), 4607-4614

CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

AB Structural modifications requiring novel synthetic chem. were made to the morpholine acetal human neurokinin-1 (hNK-1) receptor antagonist L-742694, and this resulted in the discovery of 2-(R)-(1-(R)-3,5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-oxo-1,2,4-triazol-5-yl)methyl morpholine (I). This modified compd. is a potent, long-acting hNK-1 receptor antagonist as evidenced by its ability to

displace [125 I]Substance P from hNK-1 receptors stably expressed in CHO cells ($IC_{50} = 0.09 \pm 0.06$ nM) and by the measurement of the rates of assocn. ($k_1 = 2.8 \pm 1.1 \times 10^8$ M $^{-1}$ min $^{-1}$) and dissocn. ($k_{-1} = 0.0054 \pm 0.003$ min $^{-1}$) of I from hNK-1 expressed in Sf9 membranes which yields $K_d = 19 \pm 12$ pM and a $t_{1/2}$ for receptor occupancy equal to 154 ± 75 min. Inflammation in the guinea pig induced by a resiniferatoxin challenge (with NK-1 receptor activation mediating the subsequent increase in vascular permeability) is inhibited in a dose-dependent manner by the oral preadministration of I (IC_{50} (1 h) = 0.008 mg/kg; IC_{90} (24 h) = 1.8 mg/kg), indicating that this compd. has good oral bioavailability and peripheral duration of action. Central hNK-1 receptor stimulation is also inhibited by the systemic preadministration of I as shown by its ability to block an NK-1 agonist-induced foot tapping response in gerbils (IC_{50} (4 h) = 0.04 \pm 0.006 mg/kg; IC_{50} (24 h) = 0.33 \pm 0.017 mg/kg) and by its antiemetic actions in the ferret against cisplatin challenge. The activity of I at extended time points in these preclin. animal models sets it apart from earlier morpholine antagonists (such as L-742694), and the piperidine antagonists CP 122721 and GR 205171 and could prove to be an advantage in the treatment of chronic disorders related to the actions of Substance P. In part on the basis of these data, I has been identified as a potential clin. candidate for the treatment of peripheral pain, migraine, chemotherapy-induced emesis, and various psychiatric disorders.


IT 145742-28-5, CP 122721

RL: BAC (Biological activity or effector, except adverse); PRP (Properties); BIOL (Biological study)
(structural optimization of potent, orally active, long-acting morpholine acetal human **NK-1** receptor **antagonist**)

RN 145742-28-5 CA

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 24 OF 43 CA COPYRIGHT 2002 ACS

AN 130:20906 CA

TI A tachykinin **NK1** receptor **antagonist**, CP-122,721-1, attenuates kainic acid-induced seizure activity

AU Zachrisson, Olof; Lindefors, Nils; Brene, Stefan

CS Karolinska Institutet, Psychiatry Section, Department of Clinical Neuroscience, Karolinska Hospital, Stockholm, S-171 76, Swed.

SO Mol. Brain Res. (1998), 60(2), 291-295

CODEN: MBREE4; ISSN: 0169-328X

PB Elsevier Science B.V.

DT Journal

LA English

09/707,320

AB Substance P (SP) can play an important role in neuronal survival. To analyze the role of SP in excitotoxicity, kainic acid (KA) was administered to rats and in situ hybridization was used to analyze the levels of the SP encoding preprotachykinin-A (PPT-A) mRNA in striatal and hippocampal subregions 1, 4, and 24 h and 7 days after KA. In striatum and piriform cortex, PPT-A mRNA peaked 4 h after KA while in hippocampus, levels peaked after 24 h. KA caused seizures and neuronal toxicity as indicated by a redn. of the no. of neurons in the hippocampal CA1 subregion after 7 days. KA was later administered alone or following pretreatment with the tachykinin **NK1** receptor **antagonist** CP-122,721-1 (0.3 mg/kg). The pretreatment decreased seizure activity and a neg. correlation was found between seizure activity and survival of CA1 neurons. Conclusively, treatment with CP-122,721-1 has a seizure inhibiting property and may possibly counteract KA-induced nerve cell death in CA1.


IT **145742-28-5**, CP-122721

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (tachykinin **NK1** receptor **antagonist**, CP-122,721-1, attenuates kainic acid-induced seizure activity)

RN 145742-28-5 CA

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 25 OF 43 CA COPYRIGHT 2002 ACS

AN 128:230216 CA

TI Synthesis and structure-activity relationships of CP-122,721, a second-generation **NK-1** receptor **antagonist**

AU Rosen, Terry J.; Coffman, Karen J.; Mclean, Stafford; Crawford, Rosemary T.; Bryce, Dianne K.; Gohda, Yoshiko; Tsuchiya, Megumi; Nagahisa, Atsushi; Nakane, Masami; Lowe, John A., III

CS Central Research Division, Pfizer Inc., Groton, CT, 06340, USA

SO Bioorg. Med. Chem. Lett. (1998), 8(3), 281-284


CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier Science Ltd.

DT Journal

LA English

GI



AB The synthesis and SAR of benzylamine side chain analogs of the **NK**
 -1 receptor **antagonist** CP-99,994 I (X = H) are
 described. The 5-trifluoromethoxy analog, CP-122,721 I (X = CF₃), shows
 superior in vivo blockade of NK-1 receptor mediated responses.


IT **145742-21-8P 145742-23-0P 145742-28-5P**
145742-29-6P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic
 preparation); BIOL (Biological study); PREP (Preparation)
 (prepn., **neurokinin-1 receptor antagonist**
 activity, and structure activity relationship of
 (benzylamino)phenylpiperidines)

RN 145742-21-8 CA

CN 3-Piperidinamine, N-[[2-(1-methylethoxy)-5-(trifluoromethoxy)phenyl]methyl
]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145742-23-0 CA

CN 3-Piperidinamine, N-[[2-ethoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-
 , (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/707,320

RN 145742-28-5 CA

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145742-29-6 CA

CN Phenol, 2-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 26 OF 43 CA COPYRIGHT 2002 ACS

AN 126:325515 CA

TI **NK-1 receptor antagonists** for prevention of neurogenic inflammation in gene therapy

IN Piedimonte, Giovanni; Hess, Hans J.; Lowe, John A., III

PA Pfizer Inc., USA; Piedimonte, Giovanni; Hess, Hans, J.; Lowe, John, A., Iii

SO PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9713514	A1	19970417	WO 1996-IB1042	19961002
	W: CA, JP, MX, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2228572	AA	19970417	CA 1996-2228572	19961002
	EP 854720	A1	19980729	EP 1996-931199	19961002
	EP 854720	B1	19990804		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	AT 182788	E	19990815	AT 1996-931199	19961002

09/707,320


ES	2134639	T3	19991001	ES	1996-931199	19961002
JP	3041051	B2	20000515	JP	1996-514868	19961002
JP	3041051	B2	20000515	JP	1997-514868	19961002
JP	10511119	T2	19981027			
PRAI	US 1995-5002	P	19951010			
	US 1995-6344	P	19951107			
	WO 1996-IB1042	W	19961002			

AB The present invention relates to a method of preventing or treating the neurogenic inflammation assocd. with the use of viral vectors in gene therapy in a mammal, including a human, by administering to the mammal an **NK-1 receptor antagonist** (e.g., a substance P receptor antagonist).

IT **145742-21-8 145742-23-0 145742-28-5 157811-47-7**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**NK-1 receptor antagonists** for prevention of neurogenic inflammation in gene therapy)


RN 145742-21-8 CA
CN 3-Piperidinamine, N-[[2-(1-methylethoxy)-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 145742-23-0 CA
CN 3-Piperidinamine, N-[[2-ethoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145742-28-5 CA
CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/707,320



RN 157811-47-7 CA

CN 3-Piperidinamine, N-[[5-(1,1-dimethylethyl)-2-methoxyphenyl]methyl]-2-[3-(trifluoromethoxy)phenyl]-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 27 OF 43 CA COPYRIGHT 2002 ACS

AN 127:29079 CA

TI **NK-1** receptor **antagonists** for the treatment of cancer

IN Howard, Harry R.

PA Pfizer Inc., USA

SO Eur. Pat. Appl., 46 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 773026	A2	19970514	EP 1996-308039	19961106
	EP 773026	A3	19991117		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CN 1154240	A	19970716	CN 1996-122019	19961024
	CA 2189501	AA	19970507	CA 1996-2189501	19961104
	AU 9670592	A1	19970515	AU 1996-70592	19961105
	AU 700520	B2	19990107		
	ZA 9609285	A	19980505	ZA 1996-9285	19961105
	US 5990125	A	19991123	US 1997-786128	19970117
	US 6194436	B1	20010227	US 1999-334369	19990616
PRAI	US 1995-7275P	P	19951106		
	US 1996-10232P	P	19960119		
	US 1997-786128	A1	19970117		

OS MARPAT 127:29079

AB **NK-1** receptor **antagonists** (e.g. Substance P receptor antagonists) (Markush included) are used for the manuf. of a

09/707,320

medicament for the treatment of cancer in a mammal, particularly for the treatment of small cell lung carcinoma, APUDoma, astrocytoma, neuroendocrine tumor, or extrapulmonary small cell carcinoma.


IT 145742-21-8 145742-23-0 145742-28-5
157811-47-7

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**Nk-1** receptor **antagonists** for the treatment of cancer)

RN 145742-21-8 CA

CN 3-Piperidinamine, N-[[2-(1-methylethoxy)-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145742-23-0 CA

CN 3-Piperidinamine, N-[[2-ethoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145742-28-5 CA

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/707,320

RN 157811-47-7 CA

CN 3-Piperidinamine, N-[[5-(1,1-dimethylethyl)-2-methoxyphenyl]methyl]-2-[3-(trifluoromethoxy)phenyl]-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 28 OF 43 CA COPYRIGHT 2002 ACS

AN 127:13461 CA

TI Antiemetic composition containing an **NK-1** receptor
antagonist

IN Gonsalves, Susan F.; Watson, John W.; Silberman, Sandra L.

PA Pfizer Inc., USA

SO Eur. Pat. Appl., 13 pp.

CODEN: EPXXDW


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 769300	A2	19970423	EP 1996-307533	19961017
	EP 769300	A3	19991124		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CN 1151893	A	19970618	CN 1996-112447	19961017
	JP 09110721	A2	19970228	JP 1996-297370	19961018
	CA 2188227	AA	19970421	CA 1996-2188227	19961018
	AU 9670279	A1	19970515	AU 1996-70279	19961018
	AU 700841	B2	19990114		
	ZA 9608790	A	19980420	ZA 1996-8790	19961018
PRAI	US 1995-5728P	P	19951020		

GI



I

AB Methods are disclosed for treating or preventing emesis in mammals, including humans, using an **NK-1 antagonist** in combination with one or more other active agents selected from (a) a glucocorticoid or corticosteroid, (b) a benzodiazepine, (c) metaclopramide and (d) an intracellular mol. scavenger.

09/707,320


IT 145742-21-8 145742-23-0 145742-28-5
157811-47-7

RL: BAC (Biological activity or effector, except adverse); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(antiemetic compn. with **NK-1** receptor
antagonist and other agent)

RN 145742-21-8 CA

CN 3-Piperidinamine, N-[[2-(1-methylethoxy)-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145742-23-0 CA

CN 3-Piperidinamine, N-[[2-ethoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145742-28-5 CA

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 157811-47-7 CA

CN 3-Piperidinamine, N-[[5-(1,1-dimethylethyl)-2-methoxyphenyl]methyl]-2-[3-(trifluoromethoxy)phenyl]-, (2S,3S)- (9CI) (CA INDEX NAME)

09/707,320

Absolute stereochemistry.



L22 ANSWER 29 OF 43 USPATFULL

AN 97:104636 USPATFULL

TI Stereoselective preparation of substituted piperidines

IN Rosen, Terry J., East Lyme, CT, United States

PA Pfizer Inc, New York, NY, United States (U.S. corporation)

PI US 5686615 19971111

AI US 1993-119149 19930920 (8)

RLI Continuation-in-part of Ser. No. US 1991-675244, filed on 26 Mar 1991, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Reamer, James H.

LREP Richardson, P. C., Ginsburg, P. H., Butterfield, G.

CLMN Number of Claims: 30

ECL Exemplary Claim: 1,7

DRWN No Drawings

LN.CNT 1519

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel processes are disclosed for the stereoselective preparation of substituted piperidine derivatives of the formulae ##STR1## wherein R.sup.1 and R.sup.2 are defined as below, useful as substance P receptor antagonists and in treating diseases mediated by an excess of substance P.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 145742-21-8P 145742-23-0P 145742-28-5P

145742-29-6P 145877-45-8P 145877-47-0P

145877-52-7P 145877-53-8P


(stereoselective prepn. of substituted piperidines)

RN 145742-21-8 USPATFULL

CN 3-Piperidinamine, N-[[2-(1-methylethoxy)-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/707,320



RN 145742-23-0 USPATFULL

CN 3-Piperidinamine, N-[[2-ethoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145742-28-5 USPATFULL

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 145742-29-6 USPATFULL

CN Phenol, 2-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/707,320



RN 145877-45-8 USPATFULL

CN 3-Piperidinamine, N-[[2-(1-methylethoxy)-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, dihydrochloride, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 145877-47-0 USPATFULL

CN 3-Piperidinamine, N-[[2-ethoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, dihydrochloride, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 145877-52-7 USPATFULL

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, dihydrochloride, (2S,3S)- (9CI) (CA INDEX NAME)

09/707,320

Absolute stereochemistry.




●2 HCl

RN 145877-53-8 USPATFULL

CN Phenol, 2-[[(2-phenyl-3-piperidinyl)amino]methyl]-4-(trifluoromethoxy)-, dihydrochloride, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

L22 ANSWER 30 OF 43 CA COPYRIGHT 2002 ACS

AN 127:60326 CA

TI Use of an **NK1** receptor **antagonist** to prevent delayed emesis after cisplatin

AU Kris, Mark G.; Radford, James E.; Pizzo, Barbara A.; Inabinet, Robin; Hesketh, Ann; Hesketh, Paul J.

CS Dept. Med., Memorial Sloan-Kettering Cancer Center and Cornell University College, New York, NY, USA

SO J. Natl. Cancer Inst. (1997), 89(11), 817-818

CODEN: JNCIEQ; ISSN: 0027-8874

PB Oxford University Press

DT Journal

LA English

AB Oral treatment of cancer patients with the **NK1** receptor **antagonist** CP-122,721 30 min prior to administration of cisplatin (.gtoreq.80 mg/m2 during <3 h) prevented or decreased both the immediate and delayed emesis usually assocd. with the latter drug.

IT 145742-28-5, CP 122721


09/707,320

RL: BAC (Biological activity or effector, except adverse); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(emesis from cisplatin in humans prevention by)

RN 145742-28-5 CA

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 31 OF 43 CA COPYRIGHT 2002 ACS

AN 125:132804 CA

TI **NK-1 receptor antagonists** for the treatment
of eye disorders

IN Hess, Hans-Juergen Ernst

PA Pfizer Inc., USA

SO PCT Int. Appl., 169 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9614845	A1	19960523	WO 1995-IB811	19950929
	W: CA, JP, MX, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2205016	AA	19960523	CA 1995-2205016	19950929
	EP 790825	A1	19970827	EP 1995-931373	19950929
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 10508837	T2	19980902	JP 1995-515865	19950929
PRAI	US 1994-336955		19941110		
	WO 1995-IB811		19950929		

OS MARPAT 125:132804

AB A method is disclosed for treating or preventing a disorder of the eye, selected from glaucoma, ocular hypertension, miosis, excess lacrimation, hyperemia, and breakdown of the blood aq. barrier in mammals, including humans, using an **NK-1 antagonist**. Also disclosed is a method of treating or preventing such disorders in mammals, including humans, using certain quinuclidine derivs., piperidine derivs., pyrrolidine derivs., azanorbornane derivs., and ethylene diamine-derived and related compds. that are substance P receptor antagonists.

IT **145742-21-8 145742-23-0 145742-28-5**
157811-47-7


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**NK-1 receptor antagonists** for the
treatment of eye disorders)

RN 145742-21-8 CA

CN 3-Piperidinamine, N-[[2-(1-methylethoxy)-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)


09/707,320

Absolute stereochemistry.




RN 145742-23-0 CA
CN 3-Piperidinamine, N-[[2-ethoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 145742-28-5 CA
CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157811-47-7 CA
CN 3-Piperidinamine, N-[[5-(1,1-dimethylethyl)-2-methoxyphenyl]methyl]-2-[3-(trifluoromethoxy)phenyl]-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 32 OF 43 CA COPYRIGHT 2002 ACS
 AN 125:185901 CA
 TI **NK-1 receptor antagonists** for the treatment
 of neuronal injury and stroke

IN Lowe, John A., III; Nelson, Robert B.

PA Pfizer Inc., USA

SO Eur. Pat. Appl., 75 pp.

CODEN: EPXXDW

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 721778	A2	19960717	EP 1995-308876	19951207
	EP 721778	A3	19991110		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
PRAI	US 1994-354705		19941212		
OS	MARPAT 125:185901				
AB	A method is provided for treating or preventing stroke, epilepsy, head trauma, spinal cord trauma, ischemic neuronal damage, such as cerebral ischemic damage from stroke or vascular occlusion (e.g., during open heart surgery), excitotoxic neuronal damage (e.g., in stroke or epilepsy) and amyotrophic lateral sclerosis in mammals, including humans, using an NK-1 antagonist . Also provided is a method of treating or preventing such disorders in mammals, including humans, using certain quinuclidine derivs., piperidine derivs., pyrrolidine derivs., azanorbornane derivs., ethylene diamine derivs. and related compds. that are substance P receptor antagonists.				
IT	145742-21-8 145742-23-0 145742-28-5 157811-47-7				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(NK-1 receptor antagonists for the treatment of neuronal injury and stroke)				
RN	145742-21-8 CA				
CN	3-Piperidinamine, N-[[2-(1-methylethoxy)-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)				


Absolute stereochemistry.

09/707,320




RN 145742-23-0 CA
CN 3-Piperidinamine, N-[[2-ethoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 145742-28-5 CA
CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157811-47-7 CA
CN 3-Piperidinamine, N-[[5-(1,1-dimethylethyl)-2-methoxyphenyl]methyl]-2-[3-(trifluoromethoxy)phenyl]-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 33 OF 43 CA COPYRIGHT 2002 ACS
 AN 125:132779 CA
 TI **NK-1** receptor **antagonists** and 5-HT3 receptor
 antagonists for the treatment of emesis

IN Gonsalves, Susan F.

PA Pfizer Inc., USA

SO Eur. Pat. Appl., 13 pp.

CODEN: EPXXDW

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 715855	A2	19960612	EP 1995-308273	19951120
	EP 715855	A3	19990120		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	US 5576317	A	19961119	US 1994-353049	19941209
	JP 08225464	A2	19960903	JP 1995-339871	19951205
	CN 1132625	A	19961009	CN 1995-120539	19951205
	CA 2164689	AA	19960610	CA 1995-2164689	19951207
	CA 2164689	C	19990316		
	AU 9540306	A1	19960620	AU 1995-40306	19951208
	AU 717776	B2	20000330		
	ZA 9510431	A	19970609	ZA 1995-10431	19951208
PRAI	US 1994-353049	A	19941209		
AB	A method is provided for treating or preventing emesis in a mammal, including a human, by administering a 5-HT3 receptor antagonist and an NK-1 receptor antagonist (e.g., a substance P receptor antagonist). Also provided are pharmaceutical compns. contg. a pharmaceutically acceptable carrier, a 5-HT3 receptor antagonist and an NK-1 receptor antagonist . The 5-HT3 antagonist is e.g. ondansetron, tropisetron, or granisetron. More than one hundred NK-1 antagonists are claimed. The antiemetic activity of NK-1 antagonist (2S,3S)-3-methoxybenzylamino-2-phenylpiperidine, alone and in combination with ondansetron, was detd.				
IT	145742-21-8 145742-23-0 145742-28-5 157811-47-7				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(NK-1 receptor antagonists and 5-HT3 receptor antagonists for the treatment of emesis)				
RN	145742-21-8 CA				
CN	3-Piperidinamine, N-[[2-(1-methylethoxy)-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)				


Absolute stereochemistry.

09/707,320




RN 145742-23-0 CA
CN 3-Piperidinamine, N-[[2-ethoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 145742-28-5 CA
CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157811-47-7 CA
CN 3-Piperidinamine, N-[[5-(1,1-dimethylethyl)-2-methoxyphenyl]methyl]-2-[3-(trifluoromethoxy)phenyl]-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 34 OF 43 CA COPYRIGHT 2002 ACS

AN 125:185903 CA

TI **NK-1 receptor antagonists** for the treatment of neuronal injury and stroke

IN Lowe, John A., III; Nelson, Robert B.

PA Pfizer Inc., USA

SO Can. Pat. Appl., 148 pp.

CODEN: CPXXEB

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 2164804	AA	19960613	CA 1995-2164804	19951208
	AU 9540304	A1	19960620	AU 1995-40304	19951208
	AU 719159	B2	20000504		
	CN 1132072	A	19961002	CN 1995-120596	19951208
	ZA 9510483	A	19970609	ZA 1995-10483	19951211
	JP 08239323	A2	19960917	JP 1995-323355	19951212
PRAI	US 1994-354702	A	19941212		

OS MARPAT 125:185903

AB **Antagonists** to **NK-1** neurokinin receptors are useful for treating or preventing stroke, epilepsy, head trauma, spinal cord trauma, ischemic neuronal damage such as cerebral ischemic damage from stroke or vascular occlusion (e.g. during open heart surgery), excitotoxic neuronal damage (e.g. in stroke or epilepsy), and amyotrophic lateral sclerosis in mammals, including humans. The antagonists include certain quinuclidine, piperidine, pyrrolidine, azanorbornane, and ethylenediamine derivs. and related compds. that are substance P receptor antagonists (no data).

IT **145742-21-8 145742-23-0 145742-28-5 157811-47-7**

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(**NK-1** receptor **antagonists** for treatment of neuronal injury and stroke)

RN 145742-21-8 CA

CN 3-Piperidinamine, N-[[2-(1-methylethoxy)-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

09/707,320




RN 145742-23-0 CA
CN 3-Piperidinamine, N-[[2-ethoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 145742-28-5 CA
CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 157811-47-7 CA
CN 3-Piperidinamine, N-[[5-(1,1-dimethylethyl)-2-methoxyphenyl]methyl]-2-[3-(trifluoromethoxy)phenyl]-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09/707,320



L22 ANSWER 35 OF 43 USPATFULL
AN 96:106489 USPATFULL
TI **NK-1** receptor **antagonists** and 5HT.sub.3
receptor antagonists for the treatment of emesis
IN Gonsalves, Susan F., Stonington, CT, United States
PA Pfizer Inc., New York, NY, United States (U.S. corporation)
PI US 5576317 19961119
AI US 1994-353049 19941209 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Nutter, Nathan M.
LREP Richardson, Peter C., Ginsburg, Paul H., DeBenedictis, Karen
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 1199

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method of treating or preventing emesis in a mammal, including a human, by administering to the mammal a 5HT.sub.3 receptor **antagonist** and an **NK-1** receptor **antagonist** (e.g., a substance P receptor antagonist). It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a 5HT.sub.3 receptor **antagonist** and an **NK-1** receptor **antagonist**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 145742-21-8 145742-23-0 145742-28-5
157811-47-7

(NK-1 receptor antagonists and 5-HT₃ receptor antagonists for the treatment of emesis)


RN 145742-21-8 USPATFULL

CN 3-Piperidinamine, N-[[2-(1-methylethoxy)-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/707,320



RN 145742-23-0 USPATFULL

CN 3-Piperidinamine, N-[[2-ethoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145742-28-5 USPATFULL

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 157811-47-7 USPATFULL

CN 3-Piperidinamine, N-[[5-(1,1-dimethylethyl)-2-methoxyphenyl]methyl]-2-[3-(trifluoromethoxy)phenyl]-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L22 ANSWER 36 OF 43 CA COPYRIGHT 2002 ACS
 AN 125:26019 CA
 TI Characterization of CP-122,721; a nonpeptide antagonist of the neurokinin NK1 receptor
 AU Mclean, S.; Ganong, A.; Seymour, P. A.; Bryce, D. K.; Crawford, R. T.; Morrone, J.; Reynolds, L. S.; Schmidt, A. W.; Zorn, S.; et al.
 CS Dep. Neurosci., Pfizer Inc., Groton, CT, 06340, USA
 SO J. Pharmacol. Exp. Ther. (1996), 277(2), 900-908
 CODEN: JPETAB; ISSN: 0022-3565
 DT Journal
 LA English
 AB CP-122,721 [(+)-(2S,3S)-3-(2-methoxy-5-trifluoromethoxybenzyl)amino-2-phenylpiperidine] interacts with high affinity ($plC_{50} = 9.8$) at the human NK1 receptor expressed in IM-9 cells. In the presence of CP-122,721, there was a redn. in B_{max} of [^{125}I]BH-SP binding with no change in affinity suggesting that CP-122,721 does not interact with the NK1 receptor in a competitive manner. In an in vitro functional assay, CP-122,721 blocked SP-induced excitation of locus ceruleus cells in guinea pig brain slices with an IC_{50} value of 7 nM. In vivo, CP-122,721 potentially blocked plasma extravasation in guinea pig lung elicited by aerosolized capsaicin (1 mM) with an $ID_{50} = 0.01$ mg/kg, p.o. Orally administered CP-122,721 antagonized Sar9, Met (O2)11-SP-induced locomotor activity in guinea pigs with an $ID_{50} = 0.2$ mg/kg suggesting good entry into the central nervous system. In addn., consistent with the insurmountable blockage obsd. in vitro, CP-122,721 (0.01, 0.03 0.3 mg/kg p.o) produced a rightward shift in the dose response curve for SP-induced hypotension in the awake dog that was accompanied by a decrease in the maximal response. Thus, in vitro and in vivo CP-122,721 appears to behave functionally as a non-competitive antagonist producing an insurmountable blockade of the actions of SP.
 IT **145742-28-5**, CP 122721
 RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
 (characterization of neurokinin **NK1** receptor **antagonist** CP-122,721)
 RN 145742-28-5 CA
 CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

09/707,320



L22 ANSWER 37 OF 43 CA COPYRIGHT 2002 ACS
AN 125:132415 CA
TI Broad spectrum antiemetic effects of CP-122,721, a tachykinin **NK1** receptor **antagonist**, in ferrets
AU Gonsalves, Susan; Watson, John; Ashton, Cynthia
CS Department of General Pharmacology, Box 384, Central Research Division, Pfizer Inc., Eastern Point Road, Groton, USA
SO Eur. J. Pharmacol. (1996), 305(1-3), 181-185
CODEN: EJPHAZ; ISSN: 0014-2999
DT Journal
LA English
AB The potent, selective, tachykinin **NK1** receptor **antagonist**, CP 122721 ([(+)-(2S,3S)-3-(2-methoxy-5-trifluoromethoxybenzyl)amino-2-phenylpiperidine)], at 0.01-1 mg/kg, s.c. reduced retching and vomiting elicited by loperamide, copper sulfate, ipecac syrup and cisplatin in a dose-dependent manner. ID50 values after s.c. administration ranged from 0.02 mg/kg (loperamide) to 0.08 mg/kg (ipecac). Oral CP 122721 reduced cisplatin-induced emesis with an ID50 of .apprx.0.08 mg/kg. The less active (2R,3R)-enantiomer, CP 132687, did not significantly suppress retching or vomiting induced by any of the emetogens. These data support the hypothesis that CP 122721 blocks emesis by a specific action at tachykinin NK1 receptors. Its broad spectrum of antiemetic activity suggests a central site of action.
IT **145742-28-5**, CP 122721
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(broad spectrum antiemetic effects of CP 122721, a tachykinin **NK1** receptor **antagonist**, in ferrets)
RN 145742-28-5 CA
CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 38 OF 43 CA COPYRIGHT 2002 ACS
AN 123:65828 CA
TI Pharmaceuticals for treatment or prevention of sunburn.

09/707,320

IN Hess, Hans-Jurgen Ernst; Nagahisa, Atsushi

PA Pfizer Inc., USA

SO Eur. Pat. Appl., 91 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 653208	A2	19950517	EP 1994-203210	19941103
	EP 653208	A3	19951011		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CA 2135837	AA	19950518	CA 1994-2135837	19941115
PRAI	US 1993-153682		19931117		

OS MARPAT 123:65828

AB The present invention relates to the use of certain quinuclidine, piperidine, azanorbornane derivs. and related compds., for the manuf. of a drug for the treatment or prevention of sunburn. The antisunburn activity of compds. that are substance P receptor antagonists was demonstrated in guinea pigs.

IT 145742-21-8 145742-23-0 145742-28-5

164790-92-5


RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceuticals for treatment or prevention of sunburn)

RN 145742-21-8 CA

CN 3-Piperidinamine, N-[[2-(1-methylethoxy)-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145742-23-0 CA

CN 3-Piperidinamine, N-[[2-ethoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/707,320

RN 145742-28-5 CA

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 164790-92-5 CA

CN 3-Piperidinamine, N-[[5-(1,1-dimethylethyl)-2-(1-methylethoxy)phenyl]methyl]-2-[3-(trifluoromethoxy)phenyl]-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 39 OF 43 CA COPYRIGHT 2002 ACS

AN 122:178403 CA

TI Substance P antagonists for the treatment of emesis

IN Desai, Manoj C.; Lowe, John A., III; Watson, John W.

PA Pfizer Inc., USA

SO Eur. Pat. Appl., 93 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 627221	A2	19941207	EP 1994-303467	19940516
	EP 627221	A3	19950802		
	EP 627221	B1	20011128		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	US 5393762	A	19950228	US 1993-72629	19930604
	AT 209490	E	20011215	AT 1994-303467	19940516
	JP 07053362	A2	19950228	JP 1994-121042	19940602
	CA 2124990	C	19990420	CA 1994-2124990	19940602
	AU 9464521	A1	19941215	AU 1994-64521	19940603
	AU 666077	B2	19960125		

09/707,320

ZA 9403896	A	19951204	ZA 1994-3896	19940603
HU 71550	A2	19951228	HU 1994-1676	19940603
CN 1121806	A	19960508	CN 1994-106917	19940603
RU 2135179	C1	19990827	RU 1994-20410	19940603


PRAI US 1993-72629 A 19930604
OS MARPAT 122:178403
AB Quinuclidine derivs., piperidine derivs., azanorbornane derivs., and related compds. (Markush included) are disclosed for treating or preventing emesis in mammals, including humans. The compd. cis-3-[(2-methoxyphenyl)methylamino]-2-benzhydrylquinuclidine inhibited cisplatinum-induced emesis in ferrets when administered at a dose of 10 mg/kg s.c., 30 min before cisplatinum exposure.
IT **145742-21-8 145742-23-0 145742-28-5 157811-47-7**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(quinuclidine derivs., piperidine derivs., azanorbornane derivs., and related compds. as substance P antagonists for the treatment of emesis)
RN 145742-21-8 CA
CN 3-Piperidinamine, N-[[2-(1-methylethoxy)-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 145742-23-0 CA
CN 3-Piperidinamine, N-[[2-ethoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145742-28-5 CA
CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/707,320



RN 157811-47-7 CA

CN 3-Piperidinamine, N-[[5-(1,1-dimethylethyl)-2-methoxyphenyl]methyl]-2-[3-(trifluoromethoxy)phenyl]-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 40 OF 43 CA COPYRIGHT 2002 ACS

AN 121:246339 CA

TI Use of tachykinin antagonists in the treatment of emesis

IN Hagan, Russell Michael; Bunce, Keith Thomas

PA Glaxo Group Ltd., UK

SO Eur. Pat. Appl., 24 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 615751	A1	19940921	EP 1994-200691	19940317
	EP 615751	B1	20011205		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	US 5547964	A	19960820	US 1994-214306	19940317
	AT 209909	E	20011215	AT 1994-200691	19940317
	JP 07002658	A2	19950106	JP 1994-74101	19940318
	JP 2000191522	A2	20000711	JP 1999-349352	19940318
	US 6329394	B1	20011211	US 1996-670021	19960625
PRAI	GB 1993-5718	A	19930319		
	US 1994-214306	A1	19940317		
	JP 1994-74101	A3	19940318		

AB The present invention relates to the use of certain tachykinin antagonists, including substance P antagonists and other neurokinin antagonists, in the treatment of emesis. For example, cis-3-[(3,5-dimethylphenyl)methoxy]-2-phenylpiperidine inhibited cisplatin-induced emesis in ferret when administered at a dose of 10 mg/kg s.c.

09/707,320


IT **145742-28-5**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tachykinin antagonist for treatment of emesis)

RN 145742-28-5 CA

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 41 OF 43 CA COPYRIGHT 2002 ACS

AN 121:195919 CA

TI Pharmaceutical agents for treatment of urinary incontinence

IN Desai, Manoj C.; Lowe, Iii John A.; Rosen, Terry J.

PA Pfizer Inc., USA

SO Eur. Pat. Appl., 59 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 610021	A1	19940810	EP 1994-300575	19940126
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	US 5340826	A	19940823	US 1993-13277	19930204
	US 5519033	A	19960521	US 1994-251493	19940531
PRAI	US 1993-13277		19930204		

AB Urinary incontinence is prevented or treated in mammals, including humans, by administration of certain quinuclidine derivs., piperidine derivs., azanorbornane derivs., ethylenediamine derivs., and related compds. which act as substance P receptor antagonists (no data). The preferred dosage range is 0.07-21 mg/kg orally or parenterally.

IT **145742-21-8 145742-23-0 145742-28-5**
157811-47-7


RL: BIOL (Biological study)
(bladder incontinence treatment with)

RN 145742-21-8 CA

CN 3-Piperidinamine, N-[[2-(1-methylethoxy)-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/707,320



RN 145742-23-0 CA

CN 3-Piperidinamine, N-[[2-ethoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145742-28-5 CA

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 157811-47-7 CA

CN 3-Piperidinamine, N-[[5-(1,1-dimethylethyl)-2-methoxyphenyl]methyl]-2-[3-(trifluoromethoxy)phenyl]-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 42 OF 43 CA COPYRIGHT 2002 ACS

AN 119:249843 CA

TI Process for the preparation of substituted cis-3-aminopiperidine substance
P receptor antagonistsIN Godek, Dennis Michael; Ruggeri, Sally Gut; Rosen, Terry Jay; Wint, Lewin
T.

PA Pfizer Inc., USA

SO PCT Int. Appl., 45 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9311110	A1	19930610	WO 1992-US9929	19921124
	W: AU, BR, CA, CS, FI, HU, JP, KR, NO, PL, RU, UA				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5364943	A	19941115	US 1991-800667	19911127
	AU 9331408	A1	19930628	AU 1993-31408	19921124
	AU 670765	B2	19960801		
	EP 619806	A1	19941019	EP 1992-925298	19921124
	EP 619806	B1	19960103		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 06510795	T2	19941201	JP 1992-510148	19921124
	JP 2587903	B2	19970305		
	BR 9206823	A	19950425	BR 1992-6823	19921124
	HU 70514	A2	19951030	HU 1994-1584	19921124
	AT 132487	E	19960115	AT 1992-925298	19921124
	ES 2081636	T3	19960301	ES 1992-925298	19921124
	RU 2081112	C1	19970610	RU 1994-27570	19921124
	PL 173659	B1	19980430	PL 1992-303982	19921124
	FI 9402457	A	19940526	FI 1994-2457	19940526
	NO 9401958	A	19940526	NO 1994-1958	19940526
	US 5663349	A	19970902	US 1994-273662	19940712
PRAI	US 1991-800667	A	19911127		
	US 1990-531265	B2	19900531		
	WO 1992-US9929	A	19921124		
OS	MARPAT 119:249843				
GI					

09/707,320



AB The title compds. I [R1 = (un)substituted aryl, (un)substituted heteroaryl, (un)substituted C3-7 cycloalkyl; R2 = (un)substituted thienyl, (un)substituted benzhydryl, (un)substituted naphthyl, (un)substituted Ph], useful as substance P receptor antagonists (no data), are prepd. by the condensation of a substituted 3-aminopyridine with R1COX (X = leaving group), R1CHO, or R1CH2X, followed by redn., hydrogenation, and resoln. Thus, 3-amino-2-chloropyridine was condensed with o-anisaldehyde, the Schiff base catalytically reduced, the intermediate reacted with PhMgBr, the intermediate hydrogenated to the corresponding piperidine, and (+)-cis-3-(2-methoxybenzylamino)-2-phenylpiperidine hydrochloride prepd. by resoln. of the racemate with (R)-(-)-mandelic acid.


IT **145742-28-5P 150891-72-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction of, in prepn. of substance P receptor antagonists)

RN 145742-28-5 CA


CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 150891-72-8 CA

CN 3-Pyridinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl- (9CI) (CA INDEX NAME)



IT **151003-35-9P**


RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and resoln. of, in prepn. of substance P receptor antagonists)

RN 151003-35-9 CA

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, hydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.

09/707,320



●x HCl


IT 150891-77-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and substance P receptor antagonist activity of)

RN 150891-77-3 CA

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, hydrochloride, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

IT 151003-36-0


RL: RCT (Reactant)
(substance P receptor antagonist activity of)

RN 151003-36-0 CA

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.


09/707,320



L22 ANSWER 43 OF 43 CA COPYRIGHT 2002 ACS
AN 118:254758 CA
TI Preparation of 3-[(fluoroalkoxy)benzylamino]piperidines and analogs as
substance P antagonists
IN Lowe, John Adams, III; Rosen, Terry Jay
PA Pfizer Inc., USA
SO PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9300331	A1	19930107	WO 1992-US3571	19920505
	W: AU, BR, CA, CS, DE, FI, HU, JP, KR, NO, PL, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
	CA 2109613	AA	19930107	CA 1992-2109613	19920505
	CA 2109613	C	19961119		
	AU 9218893	A1	19930125	AU 1992-18893	19920505
	AU 657967	B2	19950330		
	EP 589924	A1	19940406	EP 1992-911210	19920505
	EP 589924	B1	19960904		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 06506473	T2	19940721	JP 1992-510950	19920505
	JP 07110850	B4	19951129		
	HU 70499	A2	19951030	HU 1995-836	19920505
	BR 9206161	A	19951031	BR 1992-6161	19920505
	AT 142199	E	19960915	AT 1992-911210	19920505
	ES 2092113	T3	19961116	ES 1992-911210	19920505
	PL 170516	B1	19961231	PL 1992-310851	19920505
	PL 172054	B1	19970731	PL 1992-301884	19920505
	RU 2114848	C1	19980710	RU 1993-58531	19920505
	ZA 9204528	A	19921220	ZA 1992-4528	19920619
	CN 1067655	A	19930106	CN 1992-104778	19920619
	CN 1056373	B	20000913		
	US 5773450	A	19980630	US 1993-167881	19931214
	NO 9304691	A	19931217	NO 1993-4691	19931217
	NO 180715	B	19970224		
	NO 180715	C	19970604		
	HU 67434	A2	19950428	HU 1993-3668	19931220
PRAI	US 1991-717943	A2	19910620		
	WO 1992-US3571	A	19920505		
	HU 1993-3668	A	19931220		
OS	MARPAT 118:254758				
GI					

09/707,320



AB Title compds., e.g., $X_1X_2X_3C_6H_2CH_2NHR$ [R = aza(bi)cycloalkyl, etc.; X_1 = H, (fluoro)alkyl, -alkoxy; X_2, X_3 = H, halo, NO_2 , (fluoro)alkyl, -alkoxy, etc.] were prepd. as substance P antagonists (no data). Thus, 3-(F_3CO) C_6H_4CHO was cyclocondensed with $O_2N(CH_2)_3CO_2Me$ and $AcNH_4$ and the product reduced to give cis-5-amino-6-(3-trifluoromethoxyphenyl)piperidin-2-one which was reductively condensed with 2,5-(MeO)(Me $_3C$) C_6H_3CHO to give, after keto group redn., title compd. cis-I.


IT **145742-21-8P 145742-23-0P 145742-28-5P**
145742-29-6P 145877-45-8P 145877-47-0P
145877-52-7P 145877-53-8P 147232-03-9P
147249-26-1P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as substance P antagonist)

RN 145742-21-8 CA

CN 3-Piperidinamine, N-[[2-(1-methylethoxy)-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 145742-23-0 CA

CN 3-Piperidinamine, N-[[2-ethoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/707,320



RN 145742-28-5 CA

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145742-29-6 CA

CN Phenol, 2-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 145877-45-8 CA

CN 3-Piperidinamine, N-[[2-(1-methylethoxy)-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, dihydrochloride, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09/707,320




● 2 HCl

RN 145877-47-0 CA

CN 3-Piperidinamine, N-[[2-ethoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, dihydrochloride, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 145877-52-7 CA

CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, dihydrochloride, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 145877-53-8 CA

CN Phenol, 2-[[2-phenyl-3-piperidinyl]amino]methyl]-4-(trifluoromethoxy)-, dihydrochloride, (2S-cis)- (9CI) (CA INDEX NAME)

09/707,320

Absolute stereochemistry.




●2 HCl

RN 147232-03-9 CA

CN 3-Piperidinamine, N-[[5-(1,1-dimethylethyl)-2-methoxyphenyl]methyl]-2-[3-(trifluoromethoxy)phenyl]-, hydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




●x HCl

RN 147249-26-1 CA

CN 3-Piperidinamine, N-[[5-(1,1-dimethylethyl)-2-methoxyphenyl]methyl]-2-[3-(trifluoromethoxy)phenyl]-, (2R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



09/707,320

